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Duchenne muscular dystrophy (DMD) is one of the most common muscle disorders affecting 
about 1 in 3500 male births worldwide. It is caused by mutations in the gene dystrophin, the 
protein product of which is required for muscle structure and stability. Studies suggest that lack 
of dystrophin protein leads to dystrophic pathology in skeletal muscle; an important pathologic 
mediator is nuclear factor kappa B (NF-κB), a transcription factor that regulates several genes 
responsible for stress responses, cell survival and various inflammatory conditions. NF-κB is 
pathologically activated in dystrophic muscle in DMD patients and in the mdx mouse model for 
DMD. NF-κB activation in mdx mice is thought to activate protein degradation and cause 
chronic inflammation in skeletal muscle. Furthermore, pathological activation of NF-κB 
downregulates myogenic regulatory factors and interferes with muscle regeneration. Attenuation 
of NF-κB activation in mdx mice has been shown to improve muscle stability and strength. Thus, 
strategies to inhibit NF-κB activation are being actively pursued as a therapeutic option for 
DMD.  
In this thesis, I have characterized the role of A20, a deubiquitinating enzyme known to 
attenuate NF-κB activation, in skeletal muscle and examined its potential as a therapeutic target 
to attenuate NF-κB activation in DMD. I investigated the effect of A20 on NF-κB activation in 
cultured mdx and control C57BL/10 myotubes in vitro and observed its role in muscle 
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regeneration and differentiation. Characterization of A20 localization in mdx muscle 
demonstrated expression predominantly in regenerating fibers; interestingly, most were fast-
twitch muscle fibers. This correlation between expression of an NF-κB inhibitor attenuating NF-
κB activation and pathology of DMD was a promising observation to further explore the efficacy 
of A20 as a therapeutic target. To this effect, I developed adeno-associated viral vectors carrying 
A20 expression cassettes to test the therapeutic benefit of A20 over-expression in the mdx model 
of DMD. Over-expression of A20 caused a significant decrease in NF-κB activation, an overall 
reduction in regeneration and number of inflammatory cells in skeletal muscle. These studies 
show that A20 could be pursued further as a therapeutic agent for inhibition of NF-κB activation, 
not only in DMD, but also in other disorders.   
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1.0  INTRODUCTION 
1.1 SKELETAL MUSCLE 
Skeletal muscles in the human body make up about 40-50% of our body weight. Different types 
of skeletal muscles are connected to the skeleton, and their primary function is to move in co-
ordination enabling complex movements. The movement of these muscles is voluntary and is 
controlled by the central nervous system (CNS). An individual skeletal muscle may be made up 
of hundreds, or even thousands, of muscle fibers bundled together and wrapped in a connective 
tissue covering [1]. The perimysium, a layer of connective tissue, surrounds each bundle of 
muscle fibers forming a fascicle [2]. A sheath of connective tissue called the epimysium 
surrounds the fascicles of muscle. The connective tissue outside the epimysium surrounds and 
separates the muscles. Sections of the epimysium project inward to divide the muscle into 
compartments, and these compartments make up the bundle of muscle fibers that are surrounded 
by the perimysium (Figure 1). 
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Figure 1: Schematic of the structure of a skeletal muscle [3].  
Muscle consists of several individual muscle fibers. Each compartmentalized bundle of muscle fiber is surrounded 
by connective tissue called perimysium, and the whole muscle is surrounded by protective epimysium.    
 
Each skeletal muscle fiber is a single cylindrical muscle cell. Muscle fibers are made up 
of multi-nucleated cells called myotubes. The myotubes are in turn made up of several muscle 
cells called myoblasts that fuse together in a process called differentiation. Upon any form of 
injury to the muscle fibers, satellite cells residing between the cell-membrane of the muscle-cell 
known as sarcolemma, and the endomysium are stimulated to differentiate into myoblasts, and 
undergo differentiation, forming myotubes [4, 5]; these myotubes would ultimately replace the 
injured myotubes or fuse with the injured myotubes. During the maturation of the myotube, the 
centrally localized nuclei move to the periphery (Figure 2) [2]. Thus, the maturity of a muscle 
fiber can be determined by the localization of the nucleus in the fiber.  
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Figure 2: Schematic of formation of a myofiber. 
Quiescent satellite cells are activated upon muscle injury to form myoblasts. Induced expression of differentiation 
factors initiates the fusion of myoblasts to form multi-nucleated myotubes. Several myotubes come together to form 
a functional mature myofiber. 
  
Muscles consist of two types of muscle fibers: Type I (slow) and Type II (fast) [6], here 
after referred to as fast and slow fibers. The fast fibers are further classified into Type IIa and 
Type IIb fibers. Each fiber type has different properties as stated in Table 1, and perform 
different functions in the muscle. For example, slow fibers are mostly used for energy 
inexpensive activities such as standing, whereas fast fibers are utilized during strenuous activities 
like running or sprinting [6].  
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Table 1: Properties of Type I and Type II fibers. 
Properties Type I Type II 
Contraction 
Glycolytic capacity 
Fast 
Low 
Slow 
High 
Respiration Aerobic Anaerobic 
Blood supply High Low 
Fatigue resistance High Low 
 
 The hind limb skeletal muscles of mice such as quadriceps, gastrocnemius, tibialis 
anterior (TA) and the extensor digitorum longus (EDL) consist of about 90% of fast fiber type 
and about 10% of slow fiber type (Figure 3). The soleus muscle is the only exception and has a 
majority of slow type fibers [7]. This difference in number of fiber type in each muscle indicates 
their specific function and the role they play in movement. 
 
 
Figure 3: Visualization of slow fibers and fast fibers in skeletal muscle.  
Quadriceps of 8wk old C57 mice was immunostained using slow myosin heavy chain (Slow) and fast myosin heavy 
chain (Fast) to visualize slow and fast fibers respectively. 
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1.2 DUCHENNE MUSCULAR DYSTROPHY 
Muscular dystrophy is a group of genetic disorders and is characterized by progressive muscle 
weakness and atrophy among other symptoms. Of this group, Duchenne Muscular Dystrophy 
(DMD) is one of the most common of dystrophies [8]. Guillaume Benjamin Amand Duchenne, a 
French neurologist first characterized the disorder by providing some of the first clinical 
descriptions of DMD patients. DMD affects about 1 in 3500 liveborn males [8] and individuals 
suffering from this disease require a wheelchair for ambulation by their early teens and die due to 
respiratory or cardiac failure in their twenties. The disease is characterized by chronic muscle 
inflammation and muscle degeneration beginning as early as 6 months of age and progresses 
with age. This degeneration is followed by a brief burst of regeneration due to the presence of 
satellite cells [9]. However, this reserve of satellite cells is exhausted and the muscle fibers are 
replaced by fat and connective tissue. DMD is primarily caused by a mutation in the gene 
encoding for dystrophin resulting in a defective protein product [10]. Dystrophin is one of the 
cytoskeletal components of the Dystrophin-Glycoprotein Complex (DGC) (Figure 4) and is 
located on the cytoplasmic face of the sarcolemma [11]. Dystrophin is a 2.4 Mb gene present on 
the X-chromosome containing 79 exons, encoding for a 427 kDa protein [10]. Absence of this 
protein leads to the disruption of the DGC [12], causing membrane instability leading to a loss of 
muscle integrity and an increase in progressive muscle degeneration [13]. Due to muscle 
damage, high serum levels of creatine kinase, an intracellular muscle protein are also observed 
[14]. There is increased necrosis and accumulation of fibrotic tissue in muscle that leads to 
infiltration of inflammatory cells and subsequently causes muscle atrophy.   
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Figure 4: Schematic of the DGC complex. 
Dystrophin connects the actin filaments to the sarcolemma surrounding the muscle. Lack of dystrophin disrupts the 
dystrophin-glycoprotein complex and causes muscle instability. 
 
In DMD patients, fast fibers are selectively affected. They are the first fibers to 
degenerate and also the first set of fibers to regenerate before the slow fibers are affected [15]. 
Since the contraction rates of fast fibers are higher than slow fibers, absence of dystrophin might 
cause the fast fibers to become unstable faster and ultimately undergo degeneration. 
 There has been immense amount of research to find a cure for the disease, which, to date, 
have not resulted in treatments that significantly alter the morbidity and mortality rates. 
Currently, available therapies only ameliorate symptoms temporarily and support declining 
function levels. Administration of corticosteroids reduces inflammation in muscle [16]. 
However, this treatment only slows the progression rate of the muscle degeneration and partially 
improves muscle function [17]. Thus, despite characterization of the clinical phenotype over a 
century ago, there is yet a cure to be found. A mouse model with a spontaneous mutation in the 
dystrophin gene, known as mdx, was discovered to have a mutation on the X-chromosome, 
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similar to that in human patients [18]. Mdx mice have been extensively studied to understand the 
molecular mechanisms underlying the pathology of DMD, and to develop therapies to treat 
DMD. Similar to patients with DMD, mdx mice display chronic inflammation in muscle, 
progressive muscle degeneration and subsequent atrophy (Figure 5) [18]. 
 
 
Figure 5: H&E stained sections of quadriceps of 8 wk old C57 and mdx mice.  
Quadriceps from mdx mice show increased regeneration as observed by muscle fibers with centralized nuclei, 
accumulation of fibrotic tissue replacing muscle and infiltration of inflammatory molecules in muscle.   
1.3 NUCLEAR FACTOR OF KAPPA B (NF-κB) 
Absence of dystrophin causes instability of the muscle membrane, making it highly susceptible 
to muscle damage. This leads to inflammatory cytokines such as TNF-α and other molecules 
infiltrating the muscle increasing inflammation within the muscle, activating downstream 
inflammatory pathways. One of the transcription factors known to be up-regulated in muscle of 
DMD patients as well as in mdx mice is the transcription factor Nuclear factor-kappa B (NF-κB) 
[19, 20]. NF-κB was named so because it was first discovered in 1986 as a nuclear factor 
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involved in the transcription of the immunoglobulin κ light chains in B cells [21]. It is a family 
of transcription factors known as Rel/NF-κB and has since been shown to play a role in many 
important biological processes such as apoptosis, cell proliferation, stress and injury, mounting 
an innate as well as adaptive immune response [22]. The mammalian family of NF-κB consists 
of five members: p50, p52, p65 (RelA), RelB and c-Rel, and these subunits can exist as 
homodimers or heterodimers in different cell types. These 5 members of the family have a 
common Rel homology domain (RHD), which is highly conserved. The RHD plays a role in 
protein-protein interactions such as dimerization and also facilitates DNA binding at target sites 
called the κB site to initiate transcription [23]. The most commonly occurring dimers that are 
also key regulators of gene expression are the p50-p65 heterodimers [24]. Activation of the 
pathway leads to the activation of its downstream targets, including genes involved in the 
immune and inflammatory response. 
 The NF-κB signaling pathway is activated by multiple mechanisms. The two main 
mechanisms known are the classical (canonical pathway) and the alternate (non-canonical) 
pathway [25]. In the classical pathway, NF-κB is sequestered in the cytoplasm by its inhibitor 
IκB, rendering it inactive. Upon stimulation, IκB is phosphorylated by components of the IκB 
kinase (IKK) complex, then ubiquitinated by βTrCP, an E3 ubiquitin ligase [26]. IκB binds to the 
NF-κB p50/p65 dimers such that the Nuclear Localization Sequence (NLS) is masked [27, 28]. 
IκB is subsequently degraded by the ubiquitin-proteasome system, freeing NF-κB [29]. Upon 
degradation of IκB, the NLS is now exposed, causing nuclear translocation of NF-κB. IκB also 
has nuclear export sequences (NES), and has been shown to shuttle in and out of the nucleus 
[30]. The alternate pathway, on the other hand depends on the NF-κB inducing kinase (NIK) 
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induced activation of the IKKα subunit [31, 32] and leads to the phosphorylation and processing 
of p100, generating p52/RelB heterodimers [32, 33].  
 
1.3.1 Factors that trigger pathway activation 
The classical and the alternate pathways of NF-κB activation play distinct roles in different cell 
types, and are activated by different molecular cues. The classical pathway is typically activated 
by binding of TNF-α to the tumor necrosis factor type 1/2 receptors (TNFR1/2) (Figure 6). 
Lipoploysaccharide (LPS) binding to Toll-like receptor 4 (TLR4) also robustly activates the 
classical pathway [34].  T-cell receptors (TCR), B-cell receptors (BCR), or the, interleukin-1 
receptor (IL-1R) superfamily members are all implicated to play a role in triggering classical 
pathway activation [35]. Activation of the pathway in turn causes increased transcription of 
target genes encoding chemokines, cytokines, and molecules playing a role in the immune 
response. The alternative pathway, however is triggered by the activation of certain TNF 
receptor family members, including lymphotoxin β receptor (LTβR), B-cell-activating factor 
belonging to the TNF family receptor (BAFF-R), CD40, and receptor activator of NF-κB 
(RANK) [35, 36]. It is also known that some oncogenic viruses such as the Epstein-Barr virus 
(EBV) also activate the alternate pathway [37]. Stimuli that activate the alternate pathway are 
also capable of activating the classical pathway [38]. 
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Figure 6: Schematic of classical NF-κB pathway activation.  
Binding of TNF-α to the TNF receptor triggers activation of the pathway. Adaptor protein RIP1 binds to the 
receptor and gets ubiquitinated to initiate the activation of the pathway. This process then leads to the activation of 
the IKK complex consisting of IKKα, ΙΚΚβ and IKKγ. The IKK complex phosphorylates IκB which targets it for 
degradation. The p50-p65 heterodimer is free to enter the nucleus and initiate transcription of downstream targets.   
1.3.2 Regulation of the pathway 
The role of NF-κB in various pathways warrants its need to be highly regulated. Upon 
stimulation by TNF-α or IL-1β, adaptor molecules such as TAK1[39], RIP1 [40] and TRAF6 
[41] are recruited and associated with the receptor and molecules downstream of it. This leads to 
activation of ubiquitin ligase activity of TRAF6 leading to ubiquitination of IKKγ (NEMO) and 
TRAF6 itself [23]. In order for the pathway to be activated, RIP1 is also ubiquitinated [42]. The 
ubiquitinated TRAF6 then binds to TAK1, activating it, resulting in the phosphorylation of 
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IKKβ, activating it [43]. Another form of regulation in order to translocate to the nucleus is the 
phosphorylation of the p65 subunit. p65 can be phosphorylated by different kinases [44], but the 
p50-p65 heterodimer is acetylated by p300/CBP after its phosphorylation and after nuclear 
import [45]. Also, NF-κB has several feedback loops that ensure that the pathway is held in 
check. For instance, one of the downstream targets of NF-κB is its inhibitor IκBα that then helps 
sequester NF-κB by transporting it back to the cytoplasm and rendering it inactive [46]. 
A major field of research is to explore the different natural and synthetic inhibitors of 
NF-κB, in order to attenuate its activation [47, 48]. Various approaches attempted for this are 
inhibition of downstream as well as upstream effector molecules, like proteosome inhibitors such 
as MG-132 to prevent IκB degradation [49], inhibitors of IκB kinase to prevent phosphorylation 
of IκB [50], and using acetylation inhibitors to prevent acetylation of the NF-κB subunit and to 
prevent its DNA binding capacity [45]. Despite the many approaches to inhibit NF-κB developed 
to date, a greater understanding about the mechanism of NF-κB activation and subsequent 
inhibition is required. 
1.4 ROLE OF NF-κB IN DUCHENNE MUSCULAR DYSTROPHY 
Chronic activation of NF-κB is related to several disease states including cancer, cachexia, 
rheumatoid arthritis, asthma, sepsis and DMD [38, 51]. In DMD, due to muscle degeneration, 
there is a high level of inflammatory cells infiltrating muscle [52]. This leads to higher levels of 
TNF-α in muscle, increasing activation of NF-κB [19, 52]. This over expression of NF-κB leads 
to the up-regulation of the ubiquitin-proteosome pathway by up-regulation of molecules such as 
MuRF1 [53], resulting in increased protein degradation and atrophy of muscle [54]. Moreover, 
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many cytokines such as TNF-α and chemokines are downstream targets of NF-κB, promoting 
chronic muscle inflammation [55]. Also, NF-κB was found to suppress MyoD, a transcription 
factor that is required for muscle regeneration and differentiation [56]. Studies have also shown 
that blocking the NF-κB pathway improved muscle strength and regeneration capacity [57]. 
Thus, it is important to dissect out the mechanism of this pathway to identify potential drug 
targets. 
1.5 CURRENT THERAPIES TO AMELIORATE NF-κB IN DMD 
A lot of ongoing research that studies muscular dystrophy, DMD in particular, target various 
pathways affecting muscle integrity [58-61]. One of the molecules that affect the DGC complex 
is neuronal nitric oxide synthase (nNOS), and has been studied in mdx mice as a potential target 
for therapy. Proper localization of nNOS enables the components of the DGC complex to 
properly localize to the membrane, thus providing stability to the muscle membrane [62, 63]. 
Many studies target the dystrophin gene itself and correct the mutations in the gene by several 
mechanisms, including exon skipping using antisense oligonucleotides (AON) [64] or 
introducing the dystrophin gene into mice [65, 66] to enable restoration of the DGC complex and 
thus improve stability of the muscle. 
However, a significant research direction toward therapy targets the NF-κB pathway to 
decrease the severity of the pathological symptoms of DMD. There have been several 
approaches to suppress NF-κB activation in mdx mouse muscle that improve muscle health and 
stability and reduce muscle degeneration. The targets for reduction range from blockade of the 
 13 
activation of the IKK complex to reduction of inflammation in muscle by introduction of 
pharmaceuticals. These different approaches are summarized below: 
1.5.1 Pharmaceutical drugs (Anti-inflammation and fibrosis) 
There are many drugs that are used to ameliorate symptoms in DMD patients. One of the most 
common corticosteroid medications prescribed for DMD patients is prednisone [67, 68]. 
Prednisone has a glucocorticoid effect and has potent anti-inflammatory properties. Due to 
ongoing necrosis and cycles of chronic muscle degeneration and repair, there is an accumulation 
of collagen and fibrotic tissue in the muscle. Drugs such as pirfenidone [69] and losartan [70] 
have been tested in mdx mice and shown to attenuate fibrosis in skeletal muscle. A plant-based 
drug curcumin was shown to be a potent inhibitor of NF-κB pathway activation and alleviated 
dystrophic pathology in mdx mice [71]. 
1.5.2 Peptide based inhibition (Targeting the IKK complex) 
Activation of the IKK complex is one of the key steps for the activation of the NF-κB pathway 
and initiation of transcription of its downstream targets. The IKK complex consists of three 
subunits: IKKα, IKKβ and the regulatory subunit IKKγ, also known as NEMO (NF-κB essential 
modulator). In 2000, May and colleagues designed a peptide that would inhibit the interaction of 
IKKβ and NEMO, known as the NEMO binding domain (NBD) peptide, thus disrupting the 
formation of the IKK complex [72]. Delivery of the NBD peptide covalently attached to a 
protein transduction domain (PTD), which facilitates entry of the peptide into cells showed a 
significant reduction in the activation of the NF-κB pathway and improvement of dystrophic 
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pathology in mdx mice [73, 74]. Treatment with the NBD peptide was also effective in the 
dystrophin-utrophin double-knockout mice [75] that display severe muscular dystrophy 
symptoms due to the absence of both the compensatory protein utrophin and dystrophin.  
1.5.3 Proteosome inhibitors (Targeting IκB) 
The phosphorylation and subsequent proteosomal degradation of the cytoplasmic inhibitor IκB 
activates the NF-κB dimer to enter the nucleus. Proteosome inhibitors block the 26S subunit of 
the proteasome preventing the degradation of IκB, leaving the inhibitor bound to the NF-κB 
dimer, thus preventing entry of the NF-κB dimer into the nucleus. MG-132 is one of the most 
common and well-characterized proteasome inhibitors used for the treatment of dystrophy in the 
mdx mouse model. MG-132 was shown to rescue expression levels of α-sarcoglycan, β-
dystroglycan, and dystrophin, components of the DGC complex and also to restore their 
localization to the plasma membrane [76]. Treatment with MG-132 also improved muscle 
histopathology and reduced muscle membrane damage. Velcade (Bortezomib or PS-341) and 
MLN273 (PS-273) that selectively block the ubiquitin-proteosome pathway were also shown to 
reduce activation of NF-κB in skeletal muscle of mdx mice [77]. They also restored localization 
of the components of the DGC complex to the membrane.    
1.5.4 Antioxidants (Targeting ROS) 
Several studies have implicated reactive oxygen species (ROS) as a factor in increased 
inflammation in the muscle that ultimately leads to muscle atrophy. Elevated levels of oxidative 
stress have been implicated to play a role in muscle damage, weakness and possibly fibrosis [78]. 
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Oxidative stress is also thought to exacerbate the disruption of the DGC complex, and cause 
increased activation of the NF-κB pathway, and thus impair muscle health. Antioxidants such as 
coenzyme Q10 [79], genistein [80] and melatonin [81] have been shown to ameliorate DMD 
symptoms by causing reduction of the NF-κB pathway activation. Melatonin was also shown to 
reduce inflammation in erythrocytes of DMD patients [82]. Treatment of mdx mice with 
protandim, a drug that induces anti-oxidant enzymes showed a reduction in the levels of 
profibrotic factor, osteopontin [83]. Overall, oxidative stress may play a role in the pathology of 
DMD, and antioxidants could attenuate some of the symptoms [78].   
1.5.5 Gene therapy 
One of the newer approaches to treating DMD is the use of gene therapy to introduce molecules 
of interest that would help ameliorate the symptoms and pathogenesis of DMD. Many studies 
involve introduction of molecules that would inhibit NF-κB pathway activation using vehicles 
such as viral vectors. Delivery of dominant-negative IKKα and IKKβ using an AAV vector was 
shown to decrease activation of the NF-κB pathway in 11 month-old mdx mice [84]. The authors 
also observed decreased necrosis and increased muscle regeneration. This suggests that 
inhibition of NF-κB activation in muscle was capable of ameliorating dystrophic symptoms in 
skeletal muscle of mdx mice.   
 16 
1.6 TUMOR NECROSIS FACTOR α-INDUCED PROTEIN 3 (A20) 
Ubiquitination plays a very important role in NF-κB pathway activation [51, 85, 86]. Ubiquitin is 
a small 76-aa protein that is covalently attached to various substrate proteins on their lysine 
residues that either marks them for degradation via the proteasome system or modifies the 
function of the protein. This process is known as ubiquitination and requires three enzymes. The 
first enzyme is the ubiquitin-activating enzyme E1 activating free-floating ubiquitin and passes it 
on to the second enzyme, ubiquitin-conjugating enzyme E2, the main function of which is to 
recognize substrate, which then activates ubiquitin-ligase E3, the third enzyme, that transfers the 
ubiquitin molecule to the protein substrate [87]. Substrates can undergo either mono- or 
polyubiquitination, defining the protein for either functional modification or degradation. Poly-
ubiquitination through lysine 63, in general, leads to a modification of function of the substrate, 
and mono- and poly-ubiquitination of the substrate may lead to proteosomal degradation. 
Ubiquitination of upstream molecules of the NF-κB pathway such as RIP1, IKKγ, TRAF6 and 
IκB are critical for its activation and regulation. Since the NF-κB pathway plays a role in critical 
pathways such as inflammation and the immune response, the presence of several negative 
regulators keep it in check. Deubiquitinating enzymes (DUBs) such as A20 and CYLD have 
been shown to inhibit pathway activation (Figure 6).  
A20, also known as tumor necrosis factor α-induced protein 3, was first described to be 
rapidly induced by TNF-α and protect cells from cytotoxicity that could be induced by increased 
TNF-α levels [88]. This was the first evidence of A20 playing a role in the regulation of the NF-
κB pathway. A20 also plays a role in inhibiting TNF-induced apoptosis in Jurkat T cells [89]. 
A20 contains an N-terminal OTU domain and 7 C-terminal zinc-finger domains (Figure 7) [90, 
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91]. A20 deubiquitinates the adaptor protein RIP1, that binds to the TNF receptor and gets 
polyubiquitinated through lysine 63 of ubiquitin after binding of TNF-α to the receptor. A20 then 
reubiquitinates RIP1 through Lysine 48 of ubiquitin marking it for degradation, thus inhibiting 
activation [42]. Recent studies have shown that A20 also interacts with TRAF1, TRAF2 [92] and 
TRAF6 [93], regulating NF- κB activation. The zinc-finger domains play a role in facilitating the 
deubiquitination and reubiquitination properties of the enzyme [42]. 
 
 
Figure 7: Domain structure of A20 [94]. 
The N-terminal half carries an OTU-type ubiquitin protease domain. The C-terminal portion contains seven zinc 
fingers (ZFs). The OTU domain of A20 inactivates RIP by removing Lys63-linked polyubiquitin. The E3 ligase 
domain then coordinates the addition of Lys48-linked polyubiquitin, which is known to target RIP to the 
proteasome, where it is destroyed. Abbreviations: OTU - ovarian tumor.  
 
A20 plays a critical role in regulating the NF-κB pathway in many different tissues, such 
as liver, spleen and cell types such as epithelial cells and cancer cells [87, 95, 96]. Mice deficient 
in A20 die shortly after birth (6-8 weeks) and display severe inflammation in multiple tissues, 
including the liver, spleen, muscle and hypersensitivity to TNF-α [97]. A20-deficient mice have 
chronic activation of the NF-κB pathway. Recently, A20 has been associated with several 
diseases including arthritis, Crohn’s disease, Type-1 diabetes and B-cell lymphoma [96]. 
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Specifically, studies showed mutations in the A20 gene leading to a non-functional protein in 
lymphoma cell lines [98], and was proposed to play a role as a tumor suppressor gene [99]. 
However, the precise mechanism of action and molecular function of A20 are now just 
beginning to get dissected out, and further studies are needed to shed light on the role of A20 in 
inflammatory diseases and cancers. 
1.7 ADENO-ASSOCIATED VIRAL VECTORS IN GENE THERAPY 
Adeno-associated virus (AAV) is a non-enveloped particle, about 22nm in diameter with 
icosahedral symmetry [100, 101]. The AAV genome is single-stranded, approximately 4.7kb in 
length [102], and consists of two open reading frames, the rep and cap gene. The rep gene codes 
for several Rep proteins that are required for replication of the virus and the cap gene codes for 
capsid proteins that are responsible for the formation of the capsid [103]. In addition, the AAV 
genome also contains an inverted terminal repeat (ITR) sequence, that flanks the AAV genome 
[104]. The ITR sequences are essential for the rescue, packaging and integration of AAV. These 
ITRs are also required to convert the single-stranded genome into double-stranded DNA [105]. 
  Recombinant AAV (rAAV) vectors are replication-deficient viruses belonging to the 
family of Parvoviruses. They typically require the presence of a helper virus such as Adenovirus 
or Herpes simplex virus in order to cause infection [106, 107]. In the absence of a helper virus, 
however, wild-type AAV is able to integrate into the host genome, and remain in a quiescent 
state [108, 109]. The helper virus provides proteins that are required for the AAV genome to 
enter a lytic cycle and cause infection [107]. Several serotypes of AAV have been identified to 
date; the AAV serotype 2 has been most extensively studied. Different AAV serotypes display 
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differential tissue tropism due to the varied capsid-host interactions [110]. For example, heparin 
sulphate proteoglycan (HSPG) acts as a cell surface receptor for AAV2 [111], but the laminin 
receptor was identified as the receptor for AAV2, 3, 8 and 9 [112]. This differential tissue 
tropism can be exploited to express a specific gene of interest in certain tissues, but not others.  
Thus, AAV vectors are currently being studied as promising gene delivery vehicles. AAV 
is non-pathogenic and has not been associated with any diseases in humans, even though a 
majority of humans were found to be sero-positive for AAV [113]. Moreover, these viruses are 
replication-deficient and need a helper virus to replicate. Also, upon infection in mouse and large 
animal models, AAV viral vectors did not elicit a significant host immune response [105], which 
is very beneficial for gene transfer.  
1.8 A20 IN SKELETAL MUSCLE – POTENTIAL THERAPEUTIC 
As mentioned earlier, several molecules are known to inhibit the activation of the NF-κB 
pathway and have been proven effective to regulate pathway activation in muscle and achieve 
muscle health and stability. Chronic NF-κB activation leads to increased inflammation in muscle, 
which in turn leads to muscle weakness and ultimately, muscle atrophy. Several studies have 
shown that inhibiting NF-κB in the muscle results in improved regenerative capacity of muscle 
and improved muscle strength in mdx mice.  
In this thesis, I characterize A20 and its role in skeletal muscle and assess its role in NF-
κB activation and muscle regeneration. A20 is an intrinsic negative regulator of the classical 
pathway of NF-κB activation. I hypothesized that A20 can regulate the NF-κB pathway in 
muscle, and lead to improvement of muscle health. I also analyzed the overexpression of A20 in 
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muscle and asked if it could inhibit NF-κB pathway activation in muscle. These studies provided 
the potential to understand the role of A20 in muscle and to further explore a potential novel 
therapeutic to treat DMD.  
In order to achieve these goals, I did a step-by-step analysis to understand the role of A20 
in skeletal muscle. To this end, I designed three aims and discuss each aim in detail in this thesis.  
1. Characterization of A20 in skeletal muscle to understand its role in NF-κB pathway 
activation. 
This study encompasses the protein expression, mRNA levels and localization of A20 in 
skeletal muscle of normal C57 and mdx mice. I also assessed the role of A20 with respect to the 
NF-κB pathway, and its affect on muscle regeneration.  
2. Study the effect of over-expression of A20 in mdx mice, and assess its potential as a 
therapeutic target. 
This study tests the potential of A20 as a therapeutic target for DMD in skeletal muscle by 
over-expression of A20 in muscle using an AAV8 vector. I observed changes in protein levels 
and histopathology in muscle caused by over-expression of A20. 
3. Study the expression patterns of A20 in mice with heterozygous deletion of the p65 
subunit of the NF-κB pathway. 
This study assesses A20 protein levels in mdx mice deficient in the p65 subunit of the NF-
κB pathway. I assessed localization and expression of A20 in the mdx;p65+/- mice over a range of 
ages compared to mdx;p65+/+ mice.    
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2.0  CHARACTERIZATION OF A20 IN SKELETAL MUSCLE IN MDX MICE  
Copyrighted material: Parts of this chapter has been published: FASEB J. 2011, Oct 19. [Epub 
ahead of print]  
2.1 RATIONALE 
Chronic activation of the NF-κB pathway is one of the manifestations of the lack of dystrophin in 
skeletal muscle. Some negative regulators of the NF-κB pathway such as the IκBSR [114], NBD 
peptides [74] and pharmaceuticals such as curcumin [71] have been used to inhibit the pathway 
in muscle. However, these drugs have been shown to have long-term side effects, thus rendering 
the therapy insufficient and ineffective in the long run. 
I chose to explore the naturally occurring negative regulators of the NF-κB pathway in 
the body, enhancing the likelihood and feasibility that this approach could be therapeutic. Hence, 
in this study, I focused on A20, a critical negative regulator of the pathway, known to inhibit 
pathway activation in spleen, lymph nodes and the liver [96]. Since the role of A20 was 
unknown in skeletal muscle, I first characterized A20 in skeletal muscle and determined its role 
in NF-κB pathway activation. This study was done to determine the expression, localization and 
role of A20 in skeletal muscle in mdx mice.  
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2.2 INTRODUCTION 
The NF-κB signaling pathway plays a crucial role in dystrophic pathology caused by 
dystrophin deficiency [19, 38, 51, 52, 54-56] and chronic activation of NF-κB is one of the 
secondary manifestations of the lack of dystrophin protein in muscle [19, 115]. As stated earlier, 
A20 is one of the critical negative regulators of TNF-α induced activation of the NF-κB pathway 
[96, 116] and exploring its role in muscle would help understand its molecular function and help 
assess its role in the pathology of DMD.    
Even though the function of A20 in the NF-κB pathway has been studied in many 
different tissues and cell types, the role of A20 in skeletal muscle has not been reported yet. It is 
not known if A20 negatively regulates NF-κB in muscle and what role it plays in muscle 
regeneration. Ladner and colleagues in 2003 observed that overexpression of A20 in C2C12 
myotubes led to a reduction in the NF-κB pathway activation [117]. This suggested that A20 
might play its regulatory role in muscle cells too. I hypothesized that A20 would negatively 
regulate NF-κB in skeletal muscle of mdx mice. Since C2C12 is a cell line, I decided to 
characterize the functional role of A20 in primary muscle cells isolated from mdx mice and study 
its localization in mdx mice. I focused on A20 protein and mRNA expression and localization in 
hind-limb muscles of mdx mice. I also assessed the role of A20 in the modulation of the NF-κB 
pathway in the isolated muscle cells. Since NF-κB has been shown to negatively affect muscle 
regeneration, I evaluated the role of A20 in muscle regeneration. 
I characterized the A20 localization in normal and mdx mice at different ages of normal 
and mdx mice to understand the expression patterns of A20 as pathological symptoms of DMD 
begin to manifest in the mdx mouse. The classical NF-κB pathway has been shown to inhibit 
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muscle regeneration, however, the alternate pathway is thought to be required for the 
maintenance of myofibers. Therefore, I characterized the time profile of the activation of both 
the pathways over a broad range of ages in mdx mice and assessed how activation of each 
pathway affects the dystrophic pathology. I further explored the role of A20 in relation to the 
activation of each pathway and assessed how this affected regeneration of muscle.   
2.3 MATERIALS AND METHODS 
Animals and reagents: C57BL/10/J (C57) and C57BL/10ScSn-Dmdmdx/J (mdx) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME) and were housed at the 
University of Pittsburgh Animal Housing Facility and used under approval by the University of 
Pittsburgh Institutional Animal Care and Use Committee (IACUC).  
Antibodies used for western blotting and immunohistochemical analyses were A20 (sc-
22834), p65 (sc-109), p-IκB (sc-7977), p-p65 (sc-101748), RelB (sc-28689), GAPDH (sc-
25778), MyoD (sc-760), Myf-5 (sc-302), secondary antibody for Western blotting goat anti-
rabbit HRP (sc-2030) (Santa Cruz Biotechnology, Inc, Santa Cruz, CA). Monoclonal antibodies 
were used to detect myosin heavy chain (MHC, Fast and Slow) (Vector Laboratories, 
Burlingame, CA). Monoclonal antibodies to embryonic MHC (eMyHC) (F1.652), used to detect 
regenerating fibers, obtained from the Developmental Studies Hybridoma Bank, developed by 
Helen Blau (University of Iowa, Department of Biological Sciences, Iowa City, IA).  
Primary myoblast cell isolation, propagation and differentiation: Primary myoblasts 
were isolated from hind limb muscles of 4-6 week old C57 and mdx mice as previously described 
[114]. Briefly, muscle tissue samples were processed by mechanical and enzymatic (1% 
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collagenase for 2 hrs at 37°C) digestion. The slurry was filtered through an 85mm Nytex filter 
and plated on collagen-coated plates to obtain primary myoblasts. Growth media used for 
primary myoblasts consisted of F-12 nutrient mixture (Gibco, Invitrogen, Carlsbad, CA) 
supplemented with 20% FBS, 1% penicillin/streptomycin and 2.5ng/ml bFGF (Invitrogen, 
Carlsbad, CA). Myogenic cell lineage was confirmed by demonstrating capability to fuse to form 
myotubes when cultured with differentiation media as described previously [114].  
Muscle tissue processing: Hind limb muscles obtained from mdx and C57 mice were 
snap-frozen using 2-methylbutane pre-cooled on dry ice and stored at -80°C. For 
immunohistochemical analysis, tissue samples were sectioned at a thickness of 10μm and 
transferred onto slides. For biochemical and genetic analysis, tissues samples were extracted as 
described in each relevant section.  
RT-PCR analysis: Total cellular RNA was extracted from myoblasts and differentiated 
myotubes from C57 and mdx mice using TRIzol reagent (Invitrogen, Carlsbad, CA). Single-
stranded cDNA was generated using Superscript III First-strand Synthesis Supermix (Invitrogen, 
Carlsbad, CA) at 50°C for 50min; the reaction was terminated at 85°C for 5 min. Primer 
sequences for GAPDH and the GAPDH probe (VIC) were obtained from TaqMan Rodent 
GAPDH Control Reagents (Applied Biosystems, USA). Primer sequences and probe for A20 
(FAM) were designed using the Primer Express software (Applied Biosystems, USA). 
Amplification was carried out as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 
cycles of 95°C for 15s and 60°C for 1 min. PCR products were analyzed and quantified on the 
Applied Biosystems 7300 Real-time PCR System. 
siRNA assays: Myoblasts from C57 and mdx mice cultured to 80-90% confluence on 
collagen-coated plates were transfected with control (sc-37007) or A20 (sc-37655) siRNA using 
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siRNA transfection reagent and transfection medium according to the manufacturer’s protocol 
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA). The cells were incubated with 6-8µg of A20 
or control siRNA for 5 hrs at 37°C followed by a media change to differentiation media 
containing twice the normal amount of serum (DMEM with 4% horse serum, 1% 
penicillin/streptomycin) for 24 hours. Cells were then induced to differentiate using 
differentiation media containing 2% serum for 4 days.  
Muscle differentiation assay: Differentiated myotubes were fixed using 2% 
paraformaldehyde and then blocked with 10% goat serum in 1X PBS for 1 hour.  The fixed 
myotubes were incubated with rabbit anti-skeletal myosin (Sigma-Aldrich, St. Louis, MO) for 1 
hr followed by goat anti-rabbit Alexa 594 (Sigma-Aldrich, St. Louis, MO) for 1 hr, mounted 
with Dapi Fluoromount-G (SouthernBiotech, Birmingham, AL), imaged and quantified. The 
differentiation index, which reflects the degree of differentiation, is the number of nuclei present 
within myotubes divided by the total number of nuclei per field. All quantifications were 
performed using MCID software (InterFocus Imaging Ltd, Cambridge, England). 
Electrophoretic mobility shift assay (EMSA): Nuclear extracts were obtained using 
NE-PER nuclear and cytoplasmic extraction reagent (ThermoFisher Scientific, Rockford, IL) 
from C57 and mdx myoblasts treated at specific time-points with 10 ng/µl TNF-α. Protein 
concentrations of the extracts were measured using the BCA assay (ThermoFisher Scientific, 
Rockford, IL). In order to study NF-κB activity the nuclear extracts was pre-incubated with 5X 
gel shift binding buffer (Promega, Madison, WI) and nuclease-free distilled water. This was 
followed by incubation with an α-32P-deooxycytidine triphosphate (CTP)-labeled, double-
stranded DNA probe containing the NF-κB binding domain (Perkin Elmer, Waltham, MA). The 
probe was added at a count per minute (cpm) of ~100,000/µl to bring the final volume to 10µl. 
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The NF-κB probe was designed as described previously [118]. Briefly, 15bp annealing 
nucleotides were annealed to a 31bp oligonucleotide template at the 3’ end of the template 
strand. The overhang was filled in with dNTPs in conjunction with 32P dCTP using Polymerase I, 
Large (Klenow) fragment (Invitrogen, Carlsbad, CA). Labeled reactions were purified using 
MicroSpin G50 columns (GE Healthcare, Piscataway, NJ). Oligonucleotide sequences were as 
follows – NF-κB template: 5’ – cagggctggggattccccatctccacagtttcacttc – 3’; NF-κB annealing: 5’ 
– gaagtgaaactgtgg – 3’ (Integrated DNA Technologies, Inc, Coralville, IA). DNA-protein 
complexes were separated on 6% polyacrylamide gels and resolved by electrophoresis in 1X 
TBE buffer at 100V for 1 hr. The gel was then dried at 80°C for 1 hr and autoradiographed at -
80°C for 24-48 hrs. 
Western blot analysis: Total lysates from myoblasts and myotubes were obtained by 
using M-PER Mammalian Extraction reagent (ThermoFisher Scientific, Rockford, IL) for 
cultured cells and T-PER Tissue Extraction Reagent (ThermoFisher Scientific, Rockford, IL) for 
muscle tissues. Nuclear and cytoplasmic extracts were obtained using NE-PER nuclear and 
cytoplasmic extraction reagent (ThermoFisher Scientific, Rockford, IL). Lysates were run on 
10% SDS-PAGE gel for 1 hr and transferred onto a Hybond nitrocellulose membrane at 100V 
for 90 min. Membranes were blocked using blocking buffer (1X PBS with 10% goat serum) for 
1 hr, followed by incubation with specific primary antibodies and HRP-conjugated secondary 
antibodies. The blot was then incubated with electrochemiluminescence reagents (GE 
Healthcare, Piscataway, NJ) and autoradiographed to visualize protein bands.  Standard protein 
markers were run with proteins to determine protein size. All quantifications were performed 
using MCID software (InterFocus Imaging Ltd, Cambridge, England). 
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Immunohistochemical analysis: Muscle sections were thawed at room temperature for 5 
min and hydrated using 1X PBS. The sections were then blocked using blocking buffer (10% 
goat serum in 1X PBS) for 1 hr and probed with specific primary and secondary antibodies 
diluted in DAKO antibody diluent (Invitrogen, Carlsbad, CA). Sections were then washed and 
mounted using Dapi FluoromountG mounting medium in the dark. Sections that were incubated 
with anti-mouse antibodies were treated with an additional blocking step using MOM Mouse 
IgG blocking reagent (Vector Laboratories, Burlingame, CA) in 1X PBS for 1 hr.  
Statistical Analysis: All values are presented as mean ± standard deviation (SD) from 
independent experiments. Significance was determined using the 2-tailed and unpaired Student’s 
t test. p-values < 0.05 were considered significant. 
2.4 RESULTS 
2.4.1 Protein and mRNA expression of A20 in myoblasts and myotubes 
The biological role of A20 has been studied in several tissues, including lymph node and spleen 
[96], but has not been studied in skeletal muscle. Since A20 is activated by TNF-α, I induced 
myoblasts derived from hind limbs of C57 and mdx mice and differentiated myotubes using 
TNF-α and measured A20 protein expression. Since A20 is a relatively large protein (~90kd), 
protein translation takes approximately 2 hrs [119]. Hence, I assessed protein levels of A20 in 
myoblasts and myotubes treated with 10ng/µl of TNF-α at 1 hr intervals up to 5 hrs. I observed 
significantly decreased A20 protein levels in mdx myoblasts as compared to C57 myoblasts 
(Figure 7A, C). TNF-α treatment for 5 hrs did not alter A20 protein expression level in mdx 
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myoblasts. Interestingly, when I performed a similar experiment in differentiated myotubes, A20 
protein levels were low in both mdx and C57, and did not change with TNF-α treatment (Figure 
7B, C). 
 
 
 
Figure 8: Reduction in A20 expression in myoblasts, but not in myotubes from mdx mouse muscle. 
A) Myoblasts isolated from mdx and C57 mouse muscle were treated with TNF-α (10ng/µl) for 1-5 hours. Total 
lysates were extracted and analyzed for A20 protein levels by Western blotting. B) Myoblasts were induced to 
differentiate to form myotubes by changing growth media to differentiation media, followed by treatment with TNF-
α (10ng/ml) for 1-5 hrs. C) Quantification of A20 levels normalized to GAPDH for myoblast and myotube extracts. 
Asterisks indicate significant difference between C57 and mdx (p-values for 0, 1, 2, 3, 4 and 5 hrs in myoblasts are 
0.05, 0.04, 0.04, 0.07, 0.02 and 0.03, respectively; n=3 for each time point). GAPDH expression was used as a 
loading control. 
  
To analyze whether the reduced A20 expression level in mdx myoblasts was reflected in 
decreased transcription, I analyzed A20 mRNA levels by RT-PCR. Consistent with the A20 
protein expression results, levels of A20 mRNA in C57 myoblasts increased with TNF-α 
treatment of 1 hr and in C57 myotubes with TNF-α treatment of approximately 3-4 hrs (Figure 
8A, B). In mdx myoblasts and myotubes, however, I observed no increase in A20 mRNA with 5 
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hours of TNF-α treatment suggesting that the low protein expression in mdx myogenic cells is 
due to decreased transcription. 
 
 
Figure 9: Analysis of A20 mRNA levels in C57 and mdx myoblasts and myotubes. 
Relative expression of A20 mRNA levels compared to GAPDH mRNA assessed by RT-PCR in myoblasts (A) and 
myotubes (B). Asterisks indicate significant differences between C57 and mdx (p-values for 1, 2, 3, 4 and 5 hrs in 
myoblasts are 0.01, 0.53, 0.16, 0.01 and 0.04, respectively; p-values for 1, 2, 3, 4 and 5 hrs in myotubes are 0.4, 
0.05, 0.15, 0.01 and 0.01, respectively; n=3 for each time point). 
2.4.2 A20 silencing in myotubes in vitro 
A20 is a known modulator of NF-κB activation triggered by TNF-α in several cell types 
including macrophages and Jurkat T-cells [89, 120]. In order to study the effect of lowering A20 
expression in skeletal myotubes in vitro, I used siRNA to specifically knock down A20 
expression. Myoblasts from C57 and mdx mice were treated with control or A20 siRNA for 5 
hours and then induced to differentiate into myotubes. After 4 days, the differentiated myotubes 
were treated with TNF-α for 15, 30 and 60 minutes and nuclear and cytoplasmic lysates were 
collected. The efficacy of the A20 siRNA was shown by the demonstration of knock down of 
A20 protein levels with A20 siRNA but not control siRNA when treated with TNF-α for 30 and 
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60 mins (Fig 9A). Electrophoretic mobility shift assay (EMSA) was performed on nuclear 
extracts to assess NF-κB activation in the presence of A20 siRNA. I confirmed the specificity 
and efficacy of the NF-κB probe binding by competing the radioactive probe with cold wild-type 
or mutated probe at different time-points of TNF-α treatment. In nuclear extracts untreated with 
any siRNA or with control siRNA, NF-κB activation was observed within 15-30 minutes of 
TNF- addition and decreased around 60 minutes (Fig 9B). In myoblasts treated with A20 
siRNA, however, increase in NF-κB activation was observed within 15 minutes and this 
activation persisted for 60 minutes (Fig 9B). NF-κB activation was greater and more prolonged 
for mdx as compared to C57 cells. 
 
Figure 10: Knockdown of A20 causes increased NF-κB activation in C57 and mdx myotubes. 
C57 and mdx myoblasts were transfected with control and A20 siRNA and induced to differentiate into myotubes. 
A) Western blot analysis to detect A20 protein levels in mdx myotubes after treatment with control and A20 siRNA 
after treatment with TNF-α for 30 and 60 minutes. GAPDH expression was used as a loading control. B) NF-κB 
activation as determined by electrophoretic mobility shift assay was assayed in untreated myotubes and myotubes 
transfected with control or A20 siRNA and activated with TNF-α (10ng/µl) for 15, 30, 60 min.  
 
In order to confirm these results, I assessed the levels of phosphorylated IκB (p-IκB) as 
an indication of NF-κB pathway activation. I observed an increase in p-IκB levels in cytoplasmic 
extracts of both C57 and mdx myoblasts treated with A20 siRNA as compared to control siRNA 
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(Figure 10). Thus, this confirmed that knockdown of A20 led to chronic activation of the NF-κB 
pathway.  
 
 
Figure 11: Increase in Phosphorylated IκB levels upon knockdown of A20 in myotubes. 
Phosphorylated IκB levels in myotubes treated with control or A20 siRNA. Total IκB and GAPDH protein levels 
were used as a loading control.  
 
Earlier reports demonstrated that an increase in NF-κB activation in skeletal muscle 
resulted in a decrease in muscle differentiation due to down-regulation of the transcription factor 
MyoD that is required for the regeneration and differentiation of muscle [56, 114]. Since A20 
knockdown increased NF-κB activation in myotubes (Figure 9, 10), I wanted to study its effect 
on the differentiation capacity of myoblasts derived from mdx muscles. Therefore, mdx 
myoblasts were transfected with either A20 siRNA or control siRNA for 5 hrs and subsequently 
induced to differentiate into myotubes. After 4 days, myotubes were identified by expression of 
skeletal myosin heavy chain, a marker of myogenic differentiation. The differentiation index in 
myotubes treated with control siRNA was not significantly different from that of untreated 
myotubes. However, myoblasts treated with A20 siRNA show a significant delay or reduction in 
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myotube formation, which was reflected in a lower differentiation index, as compared to 
myoblasts treated with either control siRNA or no siRNA (Figure 11A, B).  
 
 
Figure 12: A20 siRNA causes impaired differentiation capacity of C57 myoblasts. 
A) C57 myoblasts that were either untreated or transfected with control or A20 siRNA were induced to differentiate 
into myotubes by growth in differentiation media for 4 days. Myotubes were identified by expression of skeletal 
myosin heavy chain (MyHC) (red) by immunohistochemistry. Nuclei were stained using Dapi (blue). Scale bar  - 
30µm. B) Quantification of differentiation was determined by the ratio of the number of nuclei within myotubes to 
the total number of nuclei (differentiation index). Approximately 6-8 fields were counted and averaged to obtain a 
standard mean. A significant delay in differentiation was observed in A20 siRNA-treated myotubes as compared to 
control siRNA (p=0.00013) and untreated myotubes (p= 0.000016), and is indicated by asterisks. ns – not 
significant.  
 
Since chronic NF-κB activation is known to inhibit muscle regeneration by suppressing 
MyoD, a transcription factor required for muscle differentiation, I speculated this impairment of 
myotube formation is due to suppression of MyoD and other myogenic factors by chronic NF-κB 
activation, caused by A20 knock down. In order to confirm this, I looked for MyoD and Myf-5 
protein levels after induction of myoblast differentiation. I observe a decrease in both MyoD and 
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Myf-5 levels after A20 knockdown (Figure 12), supporting the hypothesis that lack of A20 
impairs normal muscle differentiation. 
 
 
Figure 13: Differentiation factors MyoD and Myf-5 are down-regulated with A20 knockdown. 
Protein levels of muscle differentiation markers, MyoD, Myf-5 in muscle cells, treated with A20 or control siRNA, 
before and after induction of muscle differentiation. DM - Differentiation media. 
2.4.3 A20 expression and localization in gastrocnemius muscle of mdx mice 
To study A20 expression in skeletal muscle in vivo, I analyzed the expression levels of A20 in 
gastrocnemius muscles at weekly intervals from 3 weeks to 20 weeks of age in mdx and C57 
mice. However, only representative time-points across this age span are shown. Western blotting 
analysis revealed an up-regulation of A20 protein levels in muscle at 8-12 weeks of age in mdx 
mice represented by an increase observed at 10 weeks of age, an increase that was not observed 
in C57 mice (Figure 13A, B). A20 levels were significantly higher in mdx muscle at 10 weeks of 
age, and subsequently decreased to levels comparable to levels in C57 muscle by 14 weeks of 
age (Figure 13B). Localization of A20 by immunohistochemistry of muscle sections revealed an 
increase in the number of A20-expressing fibers between 8 and 12 weeks of age and a gradual 
decrease by 14 weeks of age (Figure 13C). To determine the fiber type of the A20-expressing 
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fibers, I performed co-localization assays. Co-localization studies in mdx mice revealed that A20 
is expressed at higher levels by those fibers that express eMyHC, a marker of muscle fiber 
regeneration; all regenerating fibers demonstrated high expression of A20. In mdx mice, the 
numbers of degenerating and regenerating fibers began to increase after 3 weeks of age, reached 
a peak at 10-11 weeks and gradually decreased by 14 weeks of age [121]. This temporal pattern 
of muscle regeneration in mdx mice correlated with the temporal pattern of A20 protein level 
increases between 8 and 12 weeks of age (Figure 13B,C).   
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Figure 14: Skeletal muscle A20 expression is higher during regeneration-degeneration cycles in mdx 
mice. 
Gastrocnemius muscles were collected from C57 and mdx mice from 3 weeks through 20 weeks of age (n=3). A20 
expression levels were measured in total muscle lysates. A) A20 protein levels were measured by Western blot.  
Representative blots of C57 and mdx muscle at 3, 7, 10, 14 and 20 weeks are shown. GAPDH expression was used 
as a loading control. B) Quantification of A20 protein levels normalized to loading control GAPDH in skeletal 
muscle of mdx compared to C57. An asterisk indicates a significant difference (p-values for 3, 7, 10, 14 and 20 
weeks are 0.05, 0.08, 0.04, 0.59 and 0.87 respectively). C) A20 localization (green) was determined by 
immunohistochemistry analysis of gastrocnemius muscle of mdx mice and co-localized with regenerating fibers, as 
determined by embryonic Myosin Heavy Chain (eMyHC) expression (red). Scale bar – 150µm. 
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Type II (glycolytic, fast) muscle fibers are preferentially involved in muscular dystrophy 
as compared to Type 1 (oxidative, slow) muscle fibers [15]. Because of our observation that 
higher levels of A20 expression were seen in regenerating fibers and knowledge that 
regenerating fibers in muscular dystrophy are largely type II, I studied the co-localization of A20 
expression and fiber type. Muscle fibers expressing high levels of A20 co-localized exclusively 
with fast myosin heavy chain (fast MyHC), a marker for type II fibers, but not with slow myosin 
heavy chain (slow MyHC), a marker for type I fibers, in both C57 and mdx mice gastrocnemius 
muscle (Figure 14). It was also shown that down-regulation of A20 expression had an effect on 
angiogenesis [122], leading to the speculation that A20 expression might lead to better repair in 
fast fibers as compared to slow fibers. 
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Figure 15: A20 exclusively localizes to type II fibers in mdx and C57 skeletal muscle. 
Immunohistochemistry analysis on gastrocnemius muscle of C57 (A) and mdx (B) mice to study co-localization of 
A20 (green) with Type II (Fast) fibers (red), immunostained with fast myosin heavy chain (Fast MyHC), and with 
Type I (Slow) fibers (red), immunostained with slow myosin heavy chain (Slow MyHC). Merge shows co-
localization (yellow). Representative images from the complete time-profile are shown. Scale bar – 150µm. 
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2.4.4 NF-κB subunits p65 and RelB expression and localization in muscle fibers of mdx 
mice 
The NF-κB signaling pathway is activated by multiple mechanisms. The two main mechanisms 
known are the classical pathway involving subunits p50 and p65 and IκB as its cytoplasmic 
inhibitor, and the alternate pathway consisting of activation of subunits p50 and RelB. I 
investigated the levels of NF-κB subunits p65 and RelB in muscle samples across the age span of 
3-20 weeks to assess the contributions of the classical and alternate pathways, respectively, of 
NF-κB activation in mdx and C57 mice. I observed that RelB protein levels in muscle were 
significantly increased in mdx mice at all time-points between 3 and 20 weeks of age as 
compared to wild-type C57 mice (Figure 15A, B). Phosphorylated p65 (p-p65) protein levels 
peaked in mdx muscle at time-points between 7 and 12 weeks of age and decreased to protein 
levels comparable to 14 and 20 weeks in C57 muscle (Figure 15C, D). 
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Figure 16: Increased expression of NF-κB subunits in skeletal muscle from mdx mice. 
Gastrocnemius muscles were collected from C57 and mdx mice from 3 weeks through 20 weeks of age (n=3). 
Western blot analysis of total muscle lysates determined protein levels of RelB (A) and p-p65 (C). GAPDH and total 
p65 were used as loading controls. B) Quantification of the RelB levels. An asterisk indicates a significant 
difference between C57 and mdx (p-values for 3, 7, 10, 14 and 20 weeks are 0.58, 0.01, 0.01, 0.05 and 0.01, 
respectively). D) Quantification of p-p65 levels. An asterisk indicates a significant difference between C57 and mdx 
(p-values for 3, 7, 10, 14 and 20 weeks are 0.54, 0.28, 0.01, 0.9 and 0.24, respectively). 
 
Because of the co-localization of high A20 expression and muscle fiber regeneration and 
our data showing that A20 down-regulates NF-κB activation in muscle cells in vitro, I 
hypothesized that NF-κB activation would be decreased in fibers that are regenerating. 
Therefore, I studied the localization patterns of p65 and RelB in muscle of mdx mice from 3-20 
weeks of age. Representative images of the entire time-profile are shown here. I observed 
reduction in levels of p65 expression in fibers that were shown to be regenerating by expression 
of eMyHC at 7 and 10 weeks of age (Figure 16A). However, I observed an increase in RelB 
expression in these regenerating fibers (Figure 16B).  
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Figure 17: Regenerating muscle fibers in mdx mice demonstrate decreased p65 and increased RelB 
expression. 
NF-κB subunit p65 (green) (A) and RelB (green) (B) were co-localized with regenerating fibers (red) 
immunostained for embryonic myosin heavy chain (eMyHC) expression in gastrocnemius muscles of mdx mice 
from 3 weeks through 20 weeks. Asterisks indicate fibers with increased p65 expression surrounding the 
regenerating fibers. Representative images from complete time-profile are shown. Scale bar – 100µm. 
2.5 DISCUSSION 
This is the first demonstration of a role for A20 in skeletal muscle. Alteration in A20 expression 
by the pathological process of muscular dystrophy in skeletal muscle of the mdx mouse model 
supports a pivotal role of A20 in skeletal muscle homeostasis maintained through the NF-κB 
signaling pathway. The largest increase in muscle A20 expression level was observed during the 
time of maximal muscle degeneration and regeneration of the mdx mouse. A20, but not p65, 
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expression co-localized with regenerating, type II fibers, suggesting that high expression of A20 
suppresses NF-κB activation and promotes muscle fiber regeneration. Studies of cultured 
primary muscle cells suggest that this process is, at least in part, cell-autonomous since knock 
down of A20 expression in primary muscle cells resulted in higher levels of NF-κB activation 
triggered by TNF-α and failure of differentiation of myoblasts to myotubes. 
My results show, for the first time, a correlation between expression of A20 in skeletal 
muscle and dystrophic pathology. A20 is expressed in skeletal muscle and plays a role in NF-κB 
regulation in muscles of mdx mice both in vitro in primary myoblasts obtained from hind limb 
muscles of mice and in vivo, in skeletal muscle. In primary myoblasts in vitro, I saw a reduction 
in differentiation capacity to myotubes and reductions of MyoD and Myf-5 protein levels in the 
absence of A20, suggesting its role in muscle differentiation. I also characterized A20 
localization in murine hind limb muscles and observed over-expression of A20 exclusively in 
regenerating fibers. These fibers showed a lower level of p65 expression suggesting negative 
regulation of the NF-κB pathway intracellularly due to A20 expression, and thus, promoting 
regeneration of the fiber. Taken together, I have established that A20 is a negative regulator of 
NF-κB signaling in skeletal muscle, and has a role in muscle differentiation and regeneration. 
Expression of A20 has been studied in several different cell types, including carcinoma 
cell lines, epithelial cells, lymphoid tissues and myotubes [96]. Ladner and colleagues showed 
that over-expression of A20 driven by the cytomegalovirus promoter in C2C12 myotubes 
effectively inhibited NF-κB activation [117]. Similar to our results in primary myogenic cells, 
they showed that A20 expression is induced in C2C12 myotubes within 1 hr of TNF-α 
activation. I observed similar activation in C57 primary myoblasts and differentiated myotubes; 
the folds of expression were higher in myoblasts than in myotubes. In contrast, I observed a 
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much lower level of expression of A20 in mdx primary myoblasts and myotubes. This was a very 
interesting and unexpected observation, since A20 is activated by TNF-α and TNF-α is 
known to be up-regulated in mdx mice [123]. I observed differences in A20 mRNA levels 
between normal and mdx myoblasts and myotubes. A20 mRNA levels increase in wild-type C57 
myoblasts (1 hr) and myotubes (3 hr) with TNF-α stimulation; however this upregulation is not 
observed in either mdx myoblasts or mdx myotubes. One possible explanation for the reduction 
of A20 expression in myogenic cells from mdx mice could be a negative self-regulation by A20 
due to its down-regulation of NF-κB activity [124]. Also, mRNA expression of A20 that is 
stimulated by TNF-αis transient [125]; this may also contribute to the reduction of A20 
expression in mdx muscle cells.   
The critical role of A20 in the regulation of the immune response was proven in mice 
deficient in A20. A20 knockout mice display severe inflammation, multi-organ tissue damage 
and die within days of birth [97]. Chronic NF-κB activation was observed in mouse embryonic 
fibroblasts obtained from these knockout mice. In tissues other than muscle, there have been 
several studies showing A20 as a critical negative regulator of NF-κB activation. A20 is also 
shown to have an anti-apoptotic function in some cell types [97], mediated by protection of cells 
from the cytotoxic effects of TNF-α [126]. In mdx and C57 myotubes, I observed an increase in 
NF-κB activation upon siRNA-mediated knock down of A20. Therefore, I demonstrated a direct 
effect of A20 on regulation of NF-κB activation in myogenic cells. Studies have shown that 
chronic activation of NF-κB in dystrophic mice contributes to chronic muscle inflammation, 
muscle damage and subsequent muscle atrophy [52, 55]. NF-κB is also known to inhibit 
differentiation in skeletal muscle as well as regeneration of muscle by inhibiting MyoD [114, 
127]. NF-κB activation is also known to inhibit myogenesis by regulation of cyclin D1 [118]. 
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Also, there are numerous other muscle-specific transcription factors such as MRF4, myogenin 
and Myf-5 that play a role in the complicated process of skeletal muscle differentiation. 
Knockdown of A20 in myoblasts impaired their capacity for differentiation [128]. I also 
observed a reduction in protein levels of two of the factors, MyoD and Myf-5, in these 
differentiating muscle cells treated with knock down of A20. This supports the hypothesis that 
A20 plays a significant role in muscle regeneration through regulation of factors required for 
differentiation.  
Skeletal muscle consists of different fiber types and very little is known about their role 
in muscular dystrophy. Webster and colleagues performed fiber typing in DMD patient skeletal 
muscle and concluded that a fast fiber subtype, type IIb fibers were preferentially involved in the 
process of muscle degeneration [15]. They also observed that regeneration occurred almost 
exclusively in type II fibers. Our observations in mdx mice are in line with these conclusions, 
since all regenerating fibers in mdx muscle were type II fibers. Also, higher levels of A20 
expression localized to type II fibers and the level of expression correlated with the phase of 
cyclical muscle fiber degeneration and regeneration in mdx mice (7-12 weeks) [121]. Taken 
together, I hypothesize that A20 expression in regenerating type II fibers might confer 
cytoprotection by the inhibition of NF-κB activation and thus promote regeneration. This 
hypothesis was confirmed by our observation of reduction of p65 expression in regenerating 
fibers. Another study also showed a reduction in p65 expression in type II fibers [129]. This 
protective mechanism by A20 is ultimately lost, as more and more fibers undergo degeneration 
due to chronic activation of the NF-κB pathway, chronic inflammation in these fibers and 
exhaustion of satellite cells ultimately resulting in loss of muscle fibers in the later stages of the 
disease. I postulate that other muscle fibers in mdx muscle that had increased p65 expression are 
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in the initial stages of undergoing degeneration. Thus, one mechanism of the role that A20 plays 
in muscle regeneration is by inhibition of activation of muscle fiber NF-κB. This is a novel 
observation and establishes the regulatory role of A20 required for muscle regeneration in mdx 
mice. 
Studies suggest that the two primary mechanisms of NF-κB activation, the classical and 
the alternate pathways, may each play a different role in myogenesis. The classical pathway, 
activated by the nuclear localization of NF-κB subunits p50 and p65, participates in the 
regulation of muscle differentiation, whereas the alternate pathway, which is activated by the 
nuclear localization of subunits p52 and RelB, participate in myofiber mitochondrial biogenesis 
[20]. Reduction in p65 expression in regenerating fibers is consistent with an inhibitory role of 
A20 on the classical pathway of NF-κB activation. In contrast, I observed an increase in RelB 
expression in regenerating muscle fibers, which is consistent with activation of the alternate 
pathway of NF-κB activation in these fibers. RelB-/- mice have been reported to display multi-
organ inflammation, and a marked increase of immune cell infiltrate in skeletal muscles [130], 
whereas p65-/- mice are embryonic lethal [127]. p65-/- mice can be rescued with an additional 
deletion of TNF-α, and these mice display accelerated and increased myogenesis, and decreased 
NF-κB activation [127]. p65+/- mice were also shown to rescue dystrophic pathology by 
displaying reduction in necrotic fibers and muscle inflammation [20]. Recent studies indicate 
that the alternate pathway of NF-κB activation promotes the contractile function and myogenic 
potential of myofibers [131]. NF-κB inducing kinase (NIK) and IKK-α were shown to play a 
role in myogenin expression and multi-nucleated myotube formation [132]. This study also 
showed that IKK-α, but not IKK-β, was required for differentiation. Both NIK and IKK-α play a 
role in the activation of the alternate pathway of NF-κB [23]. Thus, the alternate pathway of NF-
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κB activation is important for induction and maintenance of muscle fiber differentiation. 
Moreover, it is known that the alternate pathway of NF-κB activation is triggered by inhibition of 
the classical pathway [127, 133]. Our findings of increased expression of RelB and decreased 
expression of p65 in regenerating muscle fibers is consistent with activation of the alternate 
pathway and inhibition of the classical pathway of NF-κB activation as a consequence of over-
expression of A20. Taking the results of these prior studies into consideration suggests that 
down-regulation of p65 in regenerating myofibers signals RelB activation and up-regulation in 
these fibers. This implies that the direct role of A20 is to regulate the classical pathway but not 
the alternate pathway of NF-κB activation. This finding is important since it could be postulated 
that A20 delivered therapeutically would inhibit only the classical NF-κB activation pathway 
responsible for inhibition of myogenesis, and not the alternate pathway required for its 
maintenance. However, it is important to note that in humans, development of DMD pathology is 
chronically progressive. The patient declines due to myriad complications related to dystrophin 
deficiency, including muscle atrophy and cardiac and respiratory failure and exhaustion of 
progenitor cells. Here I have shown that A20 inhibits NF-κB activation and promotes muscle 
regeneration in mdx mice. However, due to chronic NF-κB activation, dystrophin-deficient 
muscle fibers ultimately degenerate and fail to regenerate due to exhaustion of muscle satellite 
cells that are required for muscle regeneration [134]. I would speculate that intervention with 
A20 as a therapeutic would be most effective at a time when enough muscle fibers remain, such 
that A20 could protect them from degeneration. A20 would help restore the muscle and prevent 
chronic activation of the NF-κB pathway, thus improving muscle strength and stability, but 
would most likely need to be instituted early in the disease process.  
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In summary, I have shown a novel mechanism in muscular dystrophy of NF-κB 
inactivation by A20 and characterized this mechanism in skeletal muscle of mdx mice. These 
observations contribute to the understanding of how inhibition of NF-κB activation has the 
potential to play an important role in the reduction of dystrophic pathology and the preservation 
of muscle strength and health. These results provide evidence that A20 plays a pivotal role in 
muscle differentiation and regeneration with the potential to inhibit NF-κB activation in DMD 
and ameliorate dystrophic pathology. Furthermore, A20 may have potential as a therapeutic 
target in DMD.  
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3.0  OVEREXPRESSION OF A20 USING AN AAV8 VIRUS IN MDX MICE 
3.1 RATIONALE 
A20 is known as a critical negative regulator of the NF-κB pathway in several cell types, 
including macrophages, and organs such as the lymph nodes and spleen. In the previous chapter, 
I established that A20 plays a role in regulating the NF-κB pathway in skeletal muscle, and 
knockdown of A20 led to impaired differentiation capacity in myoblasts. I also observed that 
A20 localizes almost exclusively in regenerating fibers. Taken together, I can conclude that A20 
plays a role in muscle regeneration, and does this through the inhibition of the classical NF-κB 
pathway. Hence, I wanted to test the therapeutic potential of A20 in mdx mice. I hypothesized 
that, if over-expressed in mdx mice, A20 would cause reduction in the chronic activation of the 
NF-κB pathway in muscle and subsequently improve muscle health. I used adeno-associated 
virus serotype 8 (AAV8) to overexpress A20 driven by a truncated muscle creatine kinase 
promoter, whose expression is limited to skeletal muscle.    
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3.2 INTRODUCTION 
Several previous studies have focused on inhibition of the NF-κB pathway activation in 
mdx mice as a therapeutic target to ameliorate the severity of DMD symptoms. Inhibition of NF-
κB in mdx mice led to improved membrane stability, enhanced regeneration, and reduced 
inflammation, improving overall health of muscle. In my previous study, A20 has been shown to 
play a critical role in the inhibition of the classical NF-κB pathway in skeletal muscle.   
rAAV vectors are being studied as promising candidates for gene therapy for a wide 
range of human diseases. Different serotypes of AAV have been shown to display distinct tissue 
tropism and transduction efficiencies. AAV serotype 8 was shown to have high transduction 
efficiency of skeletal muscle and heart [135-137]. AAV8 was also able to equally efficiently 
transduce both fast and slow fibers [138]. Studies have also shown that AAV8 was able to 
maintain expression of a transgene at therapeutic levels in rats [139]. Thus, AAV8 is an ideal 
viral vector for gene therapy in skeletal muscle. 
In this chapter, I explore the potential of A20 as a therapeutic agent to ameliorate DMD 
symptoms in mdx mice. To this end, I used AAV8 to over-express murine A20 in skeletal muscle 
of mdx mice. In order to specifically express A20 in skeletal muscle, I used the muscle-specific 
truncated muscle creatine kinase (tMCK) promoter to restrict the over-expression to skeletal 
muscle. The tMCK promoter, about 720bp in length, was generated by ligating three tandem 
copies of the MCK enhancer to its basal promoter [140]. The tMCK promoter was the strongest 
promoter among the other muscle-specific promoters tested by Wang et al [140]. The promoter 
was also shown to preferentially transduce fast-twitch fibers. This was particularly of interest, 
since fast fibers are the first to be affected by undergoing degeneration in DMD patients. The 
promoter, however, was shown to have weak expression in heart, diaphragm and liver [140]. 
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I assessed the effect of over-expression of A20 on the NF-κB pathway activation 
compared to mice treated with saline. I assessed the protein levels of the transcription factors 
required for muscle differentiation. I also studied the effect of A20 over-expression on muscle 
regeneration and overall muscle pathology. I assessed levels of necrosis in the muscles, and 
evaluated the degree and type of inflammatory cell infiltration in skeletal muscle. The lack of 
significant levels of direct expression from the tMCK promoter in the diaphragm provided the 
opportunity to assess whether overexpression of A20 in other skeletal muscles would have a 
remote effect on the diaphragm. 
3.3 MATERIALS AND METHODS 
Mice and Reagents: C57BL/10ScSn-Dmdmdx/J (mdx) mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME) and were housed at the University of Pittsburgh Animal 
Housing Facility and used under approval by the University of Pittsburgh Institutional Animal 
Care and Use Committee (IACUC).  
Antibodies used for western blotting and immunohistochemical analyses were A20 (sc-
22834), RelB (sc-28689), GAPDH (sc-25778), MyoD (sc-760), Myf-5 (sc-302), secondary 
antibody for Western blotting goat anti-rabbit HRP (sc-2030) (Santa Cruz Biotechnology, Inc, 
Santa Cruz, CA). Antibody for CD4 T-cells (16-0041-81) was obtained from ebiosciences, San 
Diego, CA, for CD8 T-cells and secondary antibody biotinylated goat anti-rat IgG were obtained 
from Pharmingen; San Jose, CA. Monoclonal antibodies were used to detect myosin heavy chain 
(MHC, Fast and Slow) (Vector Laboratories, Burlingame, CA). Monoclonal antibodies to 
embryonic MHC (eMyHC) (F1.652), used to detect regenerating fibers, obtained from the 
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Developmental Studies Hybridoma Bank, developed by Helen Blau (University of Iowa, 
Department of Biological Sciences, Iowa City, IA).  
Virus preparation and injections: The recombinant AAV8-tMCK-A20 vector used in 
this study was constructed using a murine A20 plasmid that was obtained from BCCM/LMBP 
Plasmid collection, Belgium (LMBP 4801). The tMCK promoter used for the study was obtained 
from Dr. Bing Wang (University of Pittsburgh, PA). The AAV vector contains inverted terminal 
repeats of the viral genome and packaging signal, but does not contain any other viral coding 
sequences. AAV-293 cells were used for large-scale virus production. The viral titer was 
quantified using quantitative dot blot assays.  
Neonatal mdx pups (2-3 days old) were injected intraperitoneally using a sterile needle 
with 6.25 x 1010 vector genomes in a volume of about 30µl. The mice were sacrificed at 8 weeks 
to collect muscles. Saline injected, age-matched mice were used as a control.   
Electrophoretic mobility shift assay (EMSA): Nuclear extracts were obtained using 
NE-PER nuclear and cytoplasmic extraction reagent (ThermoFisher Scientific, Rockford, IL) 
from quadriceps and diaphragms of A20- or saline-injected mdx mice. Protein concentrations of 
the extracts were measured using the BCA assay (ThermoFisher Scientific, Rockford, IL). In 
order to study NF-κB activity the nuclear extracts was pre-incubated with 5X gel shift binding 
buffer (Promega, Madison, WI) and nuclease-free dH2O. This was followed by incubation with 
an -32P-deooxycytidine triphosphate (CTP)-labeled, double-stranded DNA probe containing 
the NF-κB binding domain (Perkin Elmer, Waltham, MA). The probe was added at a count per 
minute (cpm) of ~100,000µl to bring the final volume to 10µl. The NF-κB probe was designed 
as described previously (18). Briefly, 15bp annealing nucleotides were annealed to a 31bp 
oligonucleotide template at the 3’ end of the template strand. The overhang was filled in with 
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dNTPs in conjunction with 32P dCTP using Polymerase I, Large (Klenow) fragment (Invitrogen, 
Carlsbad, CA). Labeled reactions were purified using MicroSpin G50 columns (GE Healthcare, 
Piscataway, NJ). Oligonucleotide sequences were as follows – NF-κB template: 5’ – 
cagggctggggattccccatctccacagtttcacttc – 3’; NF-κB annealing: 5’ – gaagtgaaactgtgg – 3’ 
(Integrated DNA Technologies, Inc, Coralville, IA). DNA-protein complexes were separated on 
6% polyacrylamide gels and resolved by electrophoresis in 1X TBE buffer at 100V for 1 hr. The 
gel was then dried at 80°C for 1 hr and autoradiographed at -80°C for 24-48 hrs. 
Western blot analysis: Total lysates from quadriceps ad diaphragm tissues were 
obtained using T-PER Tissue Extraction Reagent (ThermoFisher Scientific, Rockford, IL). 
Lysates were run on 10% SDS-PAGE gel for 1 hr and transferred onto a Hybond nitrocellulose 
membrane at 100V for 90 min. Membranes were blocked using blocking buffer (1X PBS with 
10% goat serum) for 1 hr, followed by incubation with specific primary antibodies and HRP-
conjugated secondary antibodies. The blot was then incubated with electrochemiluminescence 
reagents (GE Healthcare, Piscataway, NJ) and autoradiographed to visualize protein bands.  
Standard protein markers were run with proteins to determine protein size. All quantifications 
were performed using MCID software (InterFocus Imaging Ltd, Cambridge, England). 
Muscle tissue processing: Hind limb muscles and diaphragms obtained from mdx mice 
were snap-frozen using 2-methylbutane pre-cooled on dry ice and stored at -80°C. For 
immunohistochemical analysis, tissue samples were sectioned at a thickness of 10μm and 
transferred onto slides.  
Immunohistochemical analysis: Quadriceps and diaphragm sections of 10μm in 
thickness were thawed at room temperature for 5 min and hydrated using 1X PBS. The sections 
were then blocked using blocking buffer (10% goat serum in 1X PBS) for 1 hr and probed with 
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specific primary and secondary antibodies diluted in DAKO antibody diluent (Invitrogen, 
Carlsbad, CA). Sections were then washed and mounted using Dapi FluoromountG mounting 
medium in the dark. Sections that were incubated with anti-mouse antibodies were treated with 
an additional blocking step using MOM Mouse IgG blocking reagent (Vector Laboratories, 
Burlingame, CA) in 1X PBS for 1 hr.  
For CD4 and CD8 staining, I used a DAB staining protocol as described previously 
[141]. Briefly, rehydrated sections were blocked in peroxidase blocking reagent (Invitrogen, 
Carlsbad, CA) for 5 minutes, and then incubated in blocking buffer (10% goat serum in PBS) for 
1 hr. The sections were then incubated with specific primary antibodies diluted in blocking 
buffer for 1.5 hrs. Sections were incubated for 1 hour with secondary antibody, biotinylated goat 
anti-rat, diluted in DAKO antibody diluent (Invitrogen, Carlsbad, CA). Sections were incubated 
in ABC Vectastain avidin-HRP detection solution (Vector Laboratories; Burlingame, CA) for 30 
minutes at room temperature and DAB peroxidase substrate solution (Vector Laboratories; 
Burlingame, CA) for 4 minutes. Sections were counterstained with eosin to visualize muscle 
fibers. The number of infiltrating cells in each group was quantified by counting the total number 
of cells per field in a section of vector-injected quadriceps and about 8 fields per section of 2 
sections were counted for each mouse.  
Statistical Analysis: All values are presented as mean ± standard error of mean (SEM) 
from independent animals in each group. Significance was determined using the 2-tailed and 
unpaired Student’s t test. p-values < 0.05 were considered significant. 
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3.4 RESULTS 
3.4.1 Over-expression of A20 driven by a muscle-specific promoter using an AAV8 virus 
vector  
Knock down of A20 was shown to cause chronic activation of NF-κB, indicating its role in 
regulation of the pathway [142]. I hypothesized that overexpression of A20 in skeletal muscle 
would have a therapeutic benefit on muscle improving muscle health. To test this hypothesis, I 
used an AAV serotype 8 to overexpress A20 driven by the tMCK promoter that limits transgene 
expression to skeletal muscle. The schematic of the viral plasmid is shown in Figure 17. 
Neonatal mdx pups were given an intraperitoneal injection of 6.25 x 1010 vg of AAV8-tMCK-
A20. Treated mice were sacrificed and muscles collected at 8 weeks of age. Pups injected with 
saline were used as a control. I chose 8 weeks as the time-point, because the degree of 
pathological dystrophic changes in muscle in mdx mice reaches a peak around the 8-12 wks of 
age, with a subsequent decrease in the degree of pathological change. 
  
 
Figure 18: Schematic of the AAV-tMCK-A20 plasmid. 
ITR – Inverted terminal repeats, tMCK – truncated muscle creatin kinase. 
 
I first assessed A20 protein levels in skeletal muscles of the injected mice. I observed a 
1.4 fold increase in A20 protein levels in quadriceps of mdx mice injected with AAV8-tMCK-
A20 as compared to saline-treated mice (Figure 18A). However, I did not observe any significant 
difference in A20 expression in diaphragms of mdx mice treated with A20 as compared to saline 
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(Figure 18B), as expected because the tMCK promoter is known to have weak expression in the 
diaphragm. Analysis of pathological change in the diaphragm allowed me to explore whether 
A20 over-expression in other skeletal muscle could have a remote effect on diaphragm.  
 
 
Figure 19: A20 protein levels in muscles of AAV8-A20-treated mdx mice as compared with saline-
treated mdx mice.  
A) Total lysates from quadriceps and diaphragm from 8wk old mdx mice treated with AAV8-A20 or saline were 
analyzed for A20 protein levels by Western blotting. Results from three representative mice are shown. B) 
Quantification of A20 protein levels normalized to GAPDH levels are shown. Asterisk indicates significance; 
p<0.05. n=8 for quadriceps and n=5 for diaphragm. 
3.4.2 Protein levels of the alternate pathway subunit RelB, and differentiation factor, 
Myf-5 increased upon A20 treatment 
I had previously shown that A20 is upregulated in regenerating fibers in skeletal muscle of mdx 
mice. RelB, a subunit of the alternate pathway, but not p65, a member of the classical pathway, 
was also upregulated in these fibers. Hence, I wanted to assess the effect of A20 overexpression 
on the RelB protein levels. I observed an increase in RelB protein levels in quadriceps muscle of 
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mdx mice treated with AAV8-A20 (average RelB/GAPDH ratio=0.9) as compared to mice 
treated with saline (average RelB/GAPDH ratio=0.5) (Figure 19).  I also analyzed protein levels 
of MyoD, and Myf-5, transcription factors required for differentiation of muscle. I observed an 
increase in Myf-5, but not MyoD levels in quadriceps muscle of AAV8-A20 treated mdx mice 
compared to saline. These levels remained unaffected in the diaphragm of the AAV8-A20 treated 
mice compared to saline (Figure 19). 
 
 
Figure 20: Protein levels of RelB, and differentiation factors MyoD and Myf-5. 
A) Total lysates from quadriceps and diaphragm from 8wk old mdx mice treated with AAV8-A20 or saline were 
analyzed for RelB, MyoD and Myf-5 protein levels by Western blotting. Results from three representative mice are 
shown. n=8 for quadriceps and n=5 for diaphragm.  
3.4.3 A20 overexpression decreases activation of the NF-κB pathway 
A20 plays a critical role in negatively regulating the TNF-α-induced NF-κB pathway activation 
in skeletal muscle-derived cells. Knockdown of A20 in mdx myotubes caused chronic activation 
of the NF-κB pathway. I assessed NF-κB pathway activity in quadriceps and diaphragm of 
control C57 mice and mdx mice treated with either AAV8-A20 or saline. I observed a significant 
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reduction in NF-κB pathway activation when treated with AAV8-A20 as compared to saline in 
quadriceps by electrophoretic mobility shift assay (EMSA) (Figure 20A). In the diaphragm, 
however, I did not see any significant reduction in NF-κB activity (Figure 20B).    
 
 
Figure 21: EMSA to analyze NF-κB activation in mdx quadriceps and diaphragm. 
A) Nuclear extracts from quadriceps and diaphragm of C57 and mdx mice treated with AAV8-A20 or saline were 
assessed for NF-κB activity using the EMSA assay. Results from three representative mice from each group are 
shown. B) Quantification of the NF-κB activation. Band intensities from each blot were measured and averaged for 
each group. The asterisk indicates significance; p<0.05. n=3 for C57 mice, n=9 for saline-treated mdx mice, n=12 for 
A20-treated mdx mice. 
3.4.4 Overexpression of A20 causes a decrease in muscle fibers harboring centrally-
placed nuclei in quadriceps 
Due to the lack of dystrophin and chronic activation of the NF-κB pathway, mdx skeletal muscle 
fiber sarcolemma lose integrity, thus subjecting muscle tissue to protein degradation and atrophy; 
this triggers satellite cell activation which leads to muscle fiber repair and regeneration. Thus, 
myofibers undergo repeated cycles of degeneration and regeneration. Because of this chronic 
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cycle of damage and repair, myofibers do not fully mature, and thus, nuclei in regenerating 
myofibers remain centrally located. Thus, presence of centrally nucleated muscle fibers is a 
marker for this continuous cycle of degeneration and regeneration of muscle fibers. I assessed 
the effect of A20 overexpression on this process in quadriceps of mice treated with AAV8-A20 
compared to saline. I observed a significant decrease in the percentage of fibers with centrally-
placed nuclei in quadriceps, but not in the diaphragm (Figure 21A, B). 
 
 
Figure 22: Histological analysis of AAV8-A20 and saline injected muscles.  
A) Quadriceps and diaphragm from C57 mice and mdx mice treated with AAV8-A20 or saline were stained with 
hematoxylin and eosin. B) Quantification of number of centralized nuclei in quadriceps and diaphragm of saline- or 
AAV8-A20-treated mdx mice. The number of myofibers harboring centralized nuclei were counted from three fields 
per section of two sections per mouse and then averaged for each group. The asterisk indicates significance; p<0.05. 
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n=9 for saline treated mdx mice, n=12 for AAV8-A20 treated mdx mice. Scale bar-Quadriceps-150µm; Diaphragm-
100µm. 
   
3.4.5 A20 overexpression decreases regeneration, but has no effect on necrosis in skeletal 
muscle 
Since I observed a decrease in the number of fibers harboring centrally-placed nuclei and the 
decrease in this pathological finding is indicative of a reduction in the degeneration and 
regeneration in mdx muscle, I speculated that this finding was indicative of improved muscle 
health. I confirmed this by analyzing the number of regenerating fibers in quadriceps and 
diaphragm. I observed a decrease in the percentage of regenerating fibers in quadriceps (Figure 
22A, B). Interestingly, I also observed a decrease in the percentage of regenerating fibers in the 
diaphragm of treated mice (Figure 22B). 
A decreased number of fibers with centrally-placed nuclei and percent regeneration 
indicate that the muscle is undergoing fewer cycles of degeneration and regeneration. To confirm 
a decrease in degeneration and atrophy in muscle, I assessed the amount of necrotic fibers in the 
muscles. I observed no significant decrease in the percentage of necrotic fibers in quadriceps and 
the diaphragm (Figure 22C). I also observed a lot of variability for the percentage of necrotic 
fibers between mice, as illustrated in the graph (Figure 22D).  
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Figure 23: Analysis of regeneration and necrosis in quadriceps and diaphragm of mdx mice. 
A) Quadriceps and diaphragm treated with AAV8-A20 or saline were immunolabeled with either embryonic myosin 
heavy chain (eMyHC) antibody (red) or IgG (green) to assess the number of regenerating fibers and necrotic fibers, 
respectively. B) and C) Quantification of the percentage of regenerating (B) and necrotic (C) fibers. Number of 
regenerating and necrotic fibers per section were counted and plotted as a percentage of the total number of fibers. 
Two sections per mouse were counted and averaged for each group. n=9 for saline treated mdx mice, n=12 for 
AAV8-A20 treated mdx mice. 
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3.4.6  Decrease in infiltrating inflammatory T-cells in skeletal muscle of mdx mice treated 
with AAV8-A20 
Chronic inflammation in muscle is one of the causes of protein degradation and subsequent 
muscle atrophy. Chronic NF-κB activation in muscle leads to infiltration of macrophages, T-cells 
and cytokines such as TNF-α. Because overexpression of A20 caused a reduction in NF-κB 
activation in mdx mouse muscle, I analyzed quadriceps and diaphragm for the presence of CD4 
and CD8 inflammatory T-cells. In quadriceps, I observed a significant decrease in the number of 
CD4 T-cells in AAV8-A20-treated mdx mice (Figure 23A). The number of CD8 T-cells were 
however unaffected in quadriceps of AAV8-A20-treated mdx mice (Figure 23A, B). 
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Figure 24: Analysis of infiltrating CD4 and CD8 T-cells in quadriceps. 
A) Quadriceps muscles from AAV8-A20-treated or saline-treated mdx mice were immunostained for infiltrating 
CD4 and CD8 T-cells. B) For quantification, the total number of infiltrating T-cells was counted per section, and 
two sections were counted per mouse, and were averaged for each group. The asterisk indicates significance; 
p<0.05. n=9 for mdx mice treated with saline and n=12 for mdx mice treated with AAV8-A20. Scale bar – 150µm.   
3.5 DISCUSSION 
Chronic activation of the NF-κB pathway in DMD leads to many of the pathological findings in 
DMD [19, 52, 58, 143, 144] and inhibition of the pathway ameliorates many of those findings 
[145, 146].  I show the role of A20 as a potential therapeutic molecule for DMD in mdx mice. I 
assessed the pathological changes in mdx mice upon over-expression of A20 in skeletal muscle 
achieved by systemic AAV8-A20 gene delivery. I found that increased protein expression of 
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A20 led to a significant decrease in NF-κB pathway activation in quadriceps of mdx mice. I also 
observed an increase in protein levels of RelB, a subunit of the alternate pathway and Myf-5, a 
muscle transcription factor required for differentiation. Moreover, I observed a decrease in the 
number of fibers with centrally placed nuclei and a decreased percent regeneration in the 
quadriceps of mdx mice. Lastly, I detected a reduction in the number of infiltrating inflammatory 
CD4 T-cells in the quadriceps of AAV8-A20-treated mdx mice. Taken together, I conclude that 
A20 effectively reduces the activation of the classical NF-κB pathway and leads to histological 
findings of improved muscle health. These findings suggest that A20 should be explored further 
as a therapeutic molecule for treatment of DMD. 
 Expression of A20 following systemic delivery with an AAV8 vector carrying the murine 
A20 cDNA driven by the muscle-specific tMCK promoter was increased almost 1.5 fold in 
quadriceps. This seemed to be a modest increase in the A20 protein levels in the quadriceps. One 
possible reason for this could be delivery of insufficient number of viral genomes. I was able to 
inject 6.25 x 1010 vg/mouse, as the total volume that could be injected into neonatal mice was a 
limiting factor. Nonetheless, even with a 1.5 fold increase of A20 expression, I could achieve a 
significant reduction in the activation of the NF-κB pathway in skeletal muscle. This confirmed 
my hypothesis that overexpression of A20 would be able to regulate the NF-κB pathway in 
muscle. Interestingly, I also observed an increase in the expression levels of RelB, a subunit of 
the NF-κB alternate pathway. This was a very interesting observation, since I have previously 
shown that RelB is overexpressed in regenerating fibers and that A20 plays a role in muscle 
regeneration by inhibiting the classical but not the alternate pathway. In studies by others, the 
alternate pathway was shown to be required for myogenesis and maintenance of the myofibers 
[127]. Thus, I can speculate that overexpression of A20 inhibits the classical pathway and 
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promotes the up-regulation of the alternate pathway thus enhancing muscle regeneration. I also 
assessed the effect of A20 overexpression on the diaphragm, since many of the complications in 
DMD patients arise due to weakness in the diaphragm ultimately leading to respiratory failure.  
Since the tMCK promoter is known to have weak expression in the diaphragm [140], I did not 
see any increase in A20 protein levels in the diaphragm.  
 Absence of dystrophin in the muscle impairs the integrity of the muscle membrane, 
causing the muscle fibers to undergo cycles of degeneration and regeneration [147, 148]. Due to 
this constant damage to muscle, myofibers become unstable ultimately leading to protein 
degradation and muscle atrophy [147]. I analyzed the effect of overexpression of A20 on this 
cycle of damage and repair. I observed a significant decrease in the number of fibers with 
centrally placed nuclei, a well-studied marker of continuous regeneration-degeneration, in the 
quadriceps of AAV8-A20-treated mdx mice. Earlier studies have also shown that reduced 
activation of the NF-κB pathway causes decreased regeneration and increased stability of muscle 
[84, 145]. Consistent with these studies, I also observed a decrease in the number of regenerating 
fibers in quadriceps of AAV8-A20 treated mdx mice. This suggests a decrease in the damaging 
cycles of myofiber degeneration that leads to regeneration and an overall improvement in muscle 
health. Interestingly, albeit modest, this decrease in the number of regenerating fibers was also 
observed in the diaphragm. This was a very surprising observation, since I did not see any 
significant increase in A20 protein expression in the diaphragm. One possible explanation for 
this decrease could be that the weak increase in expression levels of A20 in the diaphragm was 
sufficient to dampen NF-κB activation enough to promote muscle health. I did observe decreased 
NF-κB activation in the diaphragm of AAV8-A20-treated as compared to saline-treated mdx 
mice (Figure 21), however this did not reach statistical significance (p=0.19). A detailed study 
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focusing on the expression levels of A20, perhaps driven by a ubiquitous promoter such as the 
cytomegalovirus (CMV) promoter in the diaphragm would further help elucidate this 
observation. 
The muscle pathology in DMD is thought to be caused by an imbalance between the 
amount of regeneration and the amount of necrosis in muscle tissue [147]. One of the reasons 
muscle fibers degenerate is due to NF-κB induced activation of transcription targets such as 
MuRF1 and atrogin-1 that mediate upregulation of the ubiquitin-proteosome pathway causing 
necrosis of the muscle fibers [149-151]. I analyzed the effect of A20 overexpression on the 
number of necrotic fibers in skeletal muscle of treated mdx mice. To my surprise, overexpression 
of A20 did not have any effect on necrosis in quadriceps and the diaphragm. I observed no 
change in the number of necrotic fibers in AAV8-A20-treated as compared to saline-treated mdx 
mice. Although there was a reduction in regeneration, AAV8-A20 treatment did not confer an 
effect an effect on the level of necrosis in the muscles of the treated mdx mice. One explanation 
for this could relate to the dose of A20 transgene that could be delivered to each mouse. Since, 
the A20 transgene was delivered to neonates, its early expression during development may have 
helped maintain the health and stability of muscle fibers by inhibiting activation of the NF-κB 
pathway. This could explain the reduction in the number of regenerating fibers at 8wk of age in 
the mdx mice. However, the lower transgene expression may not have been sufficient to sustain 
its function to completely inhibit NF-κB activation leading to the transcription of its downstream 
targets causing muscle fiber necrosis. Future studies analyzing the effect of the dose of the 
delivered transgene with relation to mouse age at the time of delivery would increase 
understanding of the lack of inhibition of necrosis in A20-treated skeletal muscle. 
 65 
Chronic activation of the NF-κB pathway leads to the infiltration of inflammatory cells, 
such as macrophages, and cytokines and chemokines in skeletal muscle [152]. Specifically, 
CD4-positive and CD8-positive T-cells were shown to play a role in dystrophic pathology and 
depletion of these cells in prior studies by others led to improvement of histopathology in mdx 
mice [153]. Since A20 causes reduction of NF-κB pathway activation, I speculated that this 
reduction would decrease the amount of inflammation in muscle. I observed a reduction in the 
number of infiltrating CD4 positive T-cells in the quadriceps of AAV8-A20-treated mdx mice. I 
did not, however, observe any decrease in the number of CD8 positive T-cells in these mice. 
Although, both CD4 and CD8 T-cells are known to play a role in inflammation in mdx mice, 
biopsies from DMD patients showed a predominance of CD4-positive T-cells as compared to 
CD8-positive T-cells [147, 154]. Also, CD4-positive cells were found to be localized around 
macrophages and individual muscle fibers, whereas, CD8-positive cells were scattered 
throughout muscle tissue [154]. Hence, others speculated that CD4-positive cells, and not CD8-
positive cells, played a major role in causing muscle damage via cytotoxicity [154, 155]. A better 
understanding of the specific role of A20 in the immune response is needed to further understand 
this observation. A recent study showed that AAV vectors alone were capable of activating the 
alternate pathway in HeLa cells [156]. This was a very interesting observation from a therapeutic 
point of view, since AAV-mediated transfer would be able to not only inhibit the classical 
pathway, reducing inflammation, but also promote activation of the alternate pathway, promoting 
muscle regeneration. However, control experiments using the introduction of the AAV vector 
alone in mice would shed light on its function in skeletal muscle in mice. 
In conclusion, I have shown that A20 is a potent negative regulator of the classical NF-
κB pathway and plays a role in muscle regeneration by inhibition of the pathway in mdx mice. 
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A20 mediated inhibition of the NF-κB pathway led to decreased dystrophic pathology and 
improved muscle health. Thus, AAV-mediated delivery of A20 has potential to be explored 
further as a promising therapeutic target for DMD and future studies need to be carried out to 
elucidate the exact mechanism and function of A20 over-expression in skeletal muscle.             
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4.0  CHARACTERIZATION OF A20 IN mdx;p65+/- MICE 
4.1 RATIONALE 
 
Mdx mice with a heterozygous deficiency of the p65 subunit also show improved muscle 
health and increased levels of muscle fiber regeneration [20]. Since A20 plays a role in muscle 
regeneration by reducing NF-κB pathway activation [142], I wanted to characterize the 
expression and localization of A20 in the absence of one copy of the p65 subunit. I obtained p65 
heterozygous mice, and generated mdx;p65+/- mice to assess the protein levels of A20 in these 
mice. The aim was to study A20 expression in skeletal muscle of mdx mice that also have a 
heterozygous p65 subunit deletion and is compared to mdx mice with normal p65 expression, 
over a range of ages. Since A20 was shown to inhibit the classical, but not the alternate pathway, 
characterization of A20 in the mdx mice lacking one copy of p65 would help shed light on the 
molecular function of A20 in mdx mice and help dissect the role of A20 in the dystrophic 
phenotype.   
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4.2 INTRODUCTION 
The five members of the NF-κB family are capable of forming homodimers and heterodimers, 
and each type of dimerization has a specific function in different cell types. The p65 subunit 
forms a heterodimer with the p50 subunit, and this p50-p65 heterodimer is the most commonly 
occurring and well-studied heterodimer. Upon phosphorylation and subsequent ubiquitination of 
the cytoplasmic inhibitor, IκB, the p65 subunit is phosphorylated leading to activation and 
translocation into the nucleus. 
A20 has been shown to play a role in regulating NF-κB activation in skeletal muscle 
[142]. In Chapter 2, I noted that A20 inhibited only the classical, but not the alternate pathway of 
NF-κB activation. The classical pathway consists of the heterodimer comprising NF-κB subunits 
p50 and p65 translocating into the nucleus initiating the activation of downstream NF-κB targets 
[23, 157, 158]. Chronic activation of the pathway in muscle in DMD has been shown to increase 
activity of downstream targets such as the ubiquitin-proteasome pathway [54] and increase 
cytokine expression that ultimately causes protein degradation and muscle atrophy. Negative 
regulators of the NF-κB pathway have been shown to reduce activation of the pathway and 
improve muscle stability and health [127, 144-146, 159]. Genetic perturbations such as 
homozygous deletion of the p65 subunit in mice caused embryonic lethality and liver 
degeneration [160]. Knockout of p50 in mice, the other subunit of the heterodimer and member 
of the NF-κB family, led to defects in the immune response, but displayed normal development 
[161]. Thus, it was speculated that p65 might play a unique role in early development and 
survival [160]. These mice could be rescued by a double knockout of TNF-α, due to the absence 
of TNF-α induced cytotoxicity [162]. These TNF-α-/-;p65-/- double knockout mice showed a 
significant increase in myogenesis, and decrease in muscle inflammation and thus displayed an 
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improved muscle phenotype [127, 131]. Mdx mice that had a heterozygous deficiency of p65 
also showed an improved dystrophic phenotype by displaying an increase in regeneration and 
decrease in necrosis and inflammation [20].  
I sought to characterize the protein expression profile of A20 in mdx mice with a 
heterozygous deletion of the p65 subunit at different ages. I also characterized the number of 
fibers with centrally placed nuclei and levels of regeneration and necrosis in these mice as a 
function of age.   
4.3 MATERIALS AND METHODS 
Animals and reagents: C57BL/10/J (C57) and C57BL/10ScSn-Dmdmdx/J (mdx) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME) and were housed at the 
University of Pittsburgh Animal Housing Facility and used under approval by the University of 
Pittsburgh Institutional Animal Care and Use Committee (IACUC). In order to generate the 
mdx;p65+/- mice, I crossed mdx mice with the p65+/- mice twice to get the mutation completely 
onto the mdx background. The mice were ear-tagged and genotyped and the heterozygous mice 
were chosen for the study.   
Antibodies used for western blotting and immunohistochemical analyses were A20 (sc-
22834), GAPDH (sc-25778), secondary antibody for Western blotting goat anti-rabbit HRP (sc-
2030) (Santa Cruz Biotechnology, Inc, Santa Cruz, CA). Monoclonal antibodies to embryonic 
MHC (eMyHC) (F1.652), used to detect regenerating fibers, obtained from the Developmental 
Studies Hybridoma Bank, developed by Helen Blau (University of Iowa, Department of 
Biological Sciences, Iowa City, IA). 
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Genotyping of mice: mdx mice were crossed with p65+/- mice in order to obtain 
mdx;p65+/- mice. Mice were ear-tagged for identification and their tails were clipped for 
genotyping. DNA from the tail clippings was isolated using the DNeasy Blood and Tissue kit 
(Qiagen Sciences, Maryland, USA). Briefly, clipped tails from mice were incubated in proteinase 
K overnight at 56°C. DNA was eluted using a spin-column and stored at -20°C for further use. 
I used PCR technique to genotype the mice. Primers used for the PCR were as follows: 
p65 5’ WT: cctatagaggagcagcgcggg, p65 3’ REC: aaatgtgtcagtttcatagcctgaagaacg, p65 3’ WT: 
aatcggatgtgagaggacagg. Amplification was carried out by preheating at 95°C for 10mins, 
followed by 30 cycles of 95°C for 15s, 60°C for 60s followed by final extension at 72°C for 
7mins. The PCR products were run in a 1% agarose gel for 1hr at 100V and the bands were 
visualized. 
Western blot analysis: Total lysates from muscle tissues were obtained using T-PER 
Tissue Extraction Reagent (ThermoFisher Scientific, Rockford, IL). Nuclear and cytoplasmic 
extracts were obtained using NE-PER nuclear and cytoplasmic extraction reagent (ThermoFisher 
Scientific, Rockford, IL). Lysates were run on 10% SDS-PAGE gel for 1 hr and transferred onto 
a Hybond nitrocellulose membrane at 100V for 90 min. Membranes were blocked using blocking 
buffer (1X PBS with 10% goat serum) for 1 hr, followed by incubation with specific primary 
antibodies and HRP-conjugated secondary antibodies. The blot was then incubated with 
electrochemiluminescence reagents (GE Healthcare, Piscataway, NJ) and autoradiographed to 
visualize protein bands.  Standard protein markers were run with proteins to determine protein 
size. All quantifications were performed using MCID software (InterFocus Imaging Ltd, 
Cambridge, England). 
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Muscle tissue processing: Hind limb muscles and diaphragms obtained from mdx mice 
were snap-frozen using 2-methylbutane pre-cooled on dry ice and stored at -80°C. For 
immunohistochemical analysis, tissue samples were sectioned at a thickness of 10μm and 
transferred onto slides. For biochemical and genetic analysis, tissues samples were extracted as 
described in each relevant section.  
Immunohistochemical analysis: Muscle sections were thawed at room temperature for 5 
min and hydrated using 1X PBS. The sections were then blocked using blocking buffer (10% 
goat serum in 1X PBS) for 1 hr and probed with specific primary and secondary antibodies 
diluted in DAKO antibody diluent (Invitrogen, Carlsbad, CA). Sections were then washed and 
mounted using Dapi FluoromountG mounting medium in the dark. Sections that were incubated 
with anti-mouse antibodies were treated with an additional blocking step using MOM Mouse 
IgG blocking reagent (Vector Laboratories, Burlingame, CA) in 1X PBS for 1 hr.  
Statistical Analysis: All values are presented as mean ± standard error of mean (SEM) 
from independent animals. Significance was determined using the 2-tailed and unpaired 
Student’s t test. p-values < 0.05 were considered significant. 
4.4 RESULTS 
4.4.1 A20 expression levels in different ages of the mdx;p65+/- mice 
 A time profile of the expression pattern of A20 in the quadriceps of mdx mice showed an 
increase in A20 expression around 10wks of age and gradually decreased around 14wks and 20 
wks coming back to lower levels when compared to normal C57 mice. I analyzed whether 
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decreased expression of p65 affected expression levels of A20 in mdx mice at different ages. In 
contrast to mdx;p65+/+, heterozygous deletion of p65 in mdx mice showed a decrease in A20 
expression at 7wks of age; however I observed an increase in A20 protein expression in the p65 
deficient mice at 14wk and 20 wk of age (Figure 24). This pattern of A20 expression in p65-
deleted mdx mice was similar to patterns of A20 expression at different ages in C57 mice (Figure 
24).  
 
 
Figure 25: A20 protein levels as a function of p65 dosage in mdx mice. 
Total lysates from quadriceps of C57, mdx;p65+/+ and mdx;p65+/- mice, aged 7, 14 and 20wks were analyzed for A20 
protein levels using Western blotting. GAPDH was used as a loading control. Representative results are shown. 
 
4.4.2 NF-κB activation in p65 deficient mice 
The NF-κB pathway is chronically activated in mdx mice. To assess the affect of heterozygous 
deletion of p65 on the activation of the NF-κB pathway, I performed an EMSA on nuclear 
extracts obtained from quadriceps and diaphragm of mdx;p65+/- mice. I analyzed NF-κB 
activation at different ages of these mice. As expected, I observed a decrease in NF-κB activation 
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in both the quadriceps and diaphragm of mdx mice with a heterozygous deletion of p65 (Figure 
25). This reduction of NF-κB pathway activation persisted through 20wks of age (Figure 25). 
 
 
 
Figure 26: EMSA to analyze activation of the NF-κB pathway in mdx;p65+/- mice at different ages. 
Nuclear extracts obtained from quadriceps and diaphragm of 8 wk old mdx;p65+/+ mice and 7, 14 and 20wk old 
mdx;p65+/- mice were analyzed for NF-κB pathway activation using the EMSA.   
 
4.4.3 Histological analysis of p65 deficient mice 
In past studies, heterozygous deletion of p65 in mdx mice demonstrated increases in regeneration 
and decreases in necrosis and inflammation in skeletal muscle [20]. Acharyya and colleagues 
analyzed the gastrocnemius muscle of 7wk old mdx;p65+/- mice and observed a decrease in the 
proportion of fibers with centrally placed nuclei, an increase in the number of regenerating fibers 
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and fiber size, and a decrease in the amount of infiltrating inflammatory cells and necrosis [20]. I 
decided to analyze the effect of heterozygous deletion of p65 in mdx mice in a time-profile 
manner to assess the long-term effects of the deficiency of p65 in skeletal muscle of mdx mice. I 
analyzed the percentage of fibers with centrally placed nuclei in the quadriceps muscles of 
mdx;p65+/- mice compared to mdx;p65+/+ mice at ages 7, 10, 14 and 20wks (Figure 26A). I 
observed no difference in the percentage of fibers with centrally placed nuclei in mdx;p65+/- mice 
at 7 wks of age (Figure 26B). However, I observe an increase in the number of fibers at around 
10wks of age followed by a decrease in the percentage of fibers with centrally placed nuclei at 
14wk and 20wks of age (Figure 26B).  
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Figure 27: Analysis of number of fibers with centrally placed nuclei in mdx;p65+/- mice.  
A) Sections of quadriceps from mdx;p65+/+ and mdx;p65+/- mice, aged 7, 10, 14 and 20 wks were stained with H&E 
for histological analysis. B) Quantification of the percentage of fibers with centrally placed nuclei in the muscle. 
Number of regenerating fibers were counted and plotted as a percentage of the total number of all fibers counted. 
Two sections per mouse was counted and averaged for each group. n=2-3 per age group. 
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4.4.4 Number of regenerating fibers in mdx;p65+/- mice. 
Since the percentage of fibers with centrally placed nuclei differed with age in mdx;p65+/- mice, I 
assessed the amount of regenerating fibers in these mice at different ages. Cycles of degeneration 
and regeneration in mdx mice are observed around the 7wks of age, peak at around 10 wks of age 
and gradually decline around 14wks of age. I observed a decrease in the number of regenerating 
fibers at 10wks of age in mdx;p65+/- mice as compared to mdx;p65+/+ mice (Figure 27A, B). I did 
not observe any change in the percentage of regenerating fibers at 7, 14 or 20wks of age in these 
mice (Figure 27B).  
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Figure 28: Analysis of amount of regeneration at different ages in mdx;p65+/- mice. 
A) Sections of quadriceps from mdx;p65+/+ and mdx;p65+/- mice, aged 7, 10, 14, 20 wks were immunostained with 
embryonic myosin heavy chain (eMyHC), a marker for regenerating fibers. B) Quantification of the percentage of 
regenerating fibers in the muscle. Number of regenerating fibers were counted and plotted as a percentage of the 
total number of all fibers counted. Two sections per mouse were counted and averaged for each group. n=2-3 per 
age group.   
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4.4.5 Analysis of necrosis in 10wk old p65 deficient mice 
Since I observed a sharp decrease in the percentage of regenerating fibers at 10wks of age in 
mdx;p65+/- mice, I speculated that this decrease could either be due to improved muscle health, or 
due to increased necrosis. To confirm this, I analyzed the number of necrotic fibers at this time-
point in these p65 deficient mdx mice. I observed a decrease in the number of necrotic fibers in 
mdx;p65+/- mice as compared to mdx;p65+/+ mice (Figure 28). 
 
 
 
Figure 29: Analysis of necrosis in 10wk old mdx;p65+/- mice.  
Sections of quadriceps from mdx;p65+/+ and mdx;p65+/- mice, aged 10 wks were immunostained with mouse IgG for 
detection of necrotic fibers (green). 
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4.5 DISCUSSION 
This is the first observation of the effect of heterozygous deleted p65 subunit in relation to age in 
mdx mice. I assessed the degree of dystrophic phenotype in relation to age in these mice and 
observed that mdx mice with a heterozygous p65 deletion displayed distinct histopathological 
changes in skeletal muscle depending on the age of the mice. I observed a decrease in the 
number of fibers with centrally placed nuclei in mdx;p65+/- mice later in age at 14 and 20wks, but 
not earlier, at the peak of cycles of  degeneration and regeneration, at 7 and 10wks. Interestingly, 
I observed a sharp decrease in the number of regenerating fibers during this peak at 10wks of age 
of mdx;p65+/- mice, but the percentage was unaffected before or after this peak of damage and 
repair.  Analysis of the amount of necrotic fibers in 10wk old mdx;p65+/- mice revealed a 
reduction in necrosis as compared to mdx;p65+/+ mice. These data suggest that heterozygous 
deletion of p65 in mdx mice leads to amelioration of the dystrophic phenotype specific to the age 
of the mice.  
Heterozygous deletion of the p65 subunit was shown to improve the dystrophic 
phenotype in mdx mice and enhance myogenesis in C2C12 myoblasts and muscle stem cells [20, 
127, 134]. Heterozygous deletion of the p50 subunit in mdx mice, however, failed to rescue 
dystrophic pathology [20]. The authors studied the effect of heterozygous deletion of p65 in mdx 
mice at a specific time-point at 7wks and observed an increase in the number of fibers with 
centrally placed nuclei and regenerating fibers. I decided to do a time-profile analysis of the 
change in dystrophic phenotype in the heterozygous p65-deleted mdx mice. I had observed 
earlier that A20 protein levels were increased at 10wks of age in mdx mice, the age when there 
are cycles of degeneration and regeneration taking place in skeletal muscle. These levels 
gradually decrease at 14 wks and 20 wks of age. I also observed a peak in p65 expression at 
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10wks of age in mdx mice. Thus, a time profile analysis of A20 protein expression and the 
pathology of the mdx;p65+/- mice would give a better understanding of the effect of p65 
deficiency in mdx mice. 
    I observed a reduction in NF-κB activation with heterozygous deletion of the p65 
subunit in mdx mice. This reduction of activation was observed at all ages analyzed: from 7wk to 
20 wks of age. Thus inhibition of the NF-κB pathway in mdx mice would be able to improve the 
regeneration capacity of skeletal muscle and reduce necrosis and muscle atrophy. Analysis of 
fibers with centrally placed nuclei in the mdx;p65+/- mice revealed a distinct pattern of the 
number of fibers with centrally placed nuclei in relation to the age of the mice. In mdx mice with 
normal p65 expression, the number of fibers with centralized nuclei gradually increases with age, 
and at 20 wks, about 90% of the total fibers have centrally placed nuclei. In mdx;p65+/- mice, at 
7wks, I observed no change in the percentage of fibers with centralized nuclei as compared to 
mdx mice. However, at 10wks, there is an increase in the centrally nucleated fibers, which then 
gradually decreases at 14wk and 20wks of age. A pattern emerges when we correlate this data 
with the A20 expression profile at these ages. Analysis of A20 expression in a time-profile 
manner in mdx;p65+/- mice revealed a decrease in protein levels at 7wks of age, which then 
increases at 14wk and 20wks of age. This expression profile observed was in contrast to the 
mdx;p65+/+ mice, which showed an increase in A20 protein expression at 7wks, which gradually 
decreases by 14wk and 20wks. This is an interesting observation since it suggests that there is a 
burst of regeneration taking place at 10wks in mdx;p65+/- mice, however, instead of undergoing 
degeneration and subsequent regeneration as observed in mdx mice, these regenerating fibers 
undergo maturation and become mature myofibers by 14wks of age. This is also corroborated by 
the decrease in necrosis observed in the skeletal muscle of mdx;p65+/- mice. Increased expression 
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of A20 at 14wk and 20wks indicates that A20 is also playing a role in promoting muscle 
regeneration at these ages. Thus, one can speculate that heterozygous deletion of the p65 subunit 
in mdx mice promotes myogenesis via the inhibition of the NF-κB pathway activation and 
increased expression of A20. 
In conclusion, I have shown a correlation between the p65 subunit of the NF-κB 
pathway, expression of A20 and myogenesis in the skeletal muscle of mdx mice. Deletion of the 
p65 subunit in mdx mice causes upregulation of A20 expression at later stages in life of the mdx 
mice, and helps promote and maintain myogenesis improving dystrophic pathology.    
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5.0  CONCLUSIONS AND DISCUSSION 
Despite the clinical description of DMD over a century ago, no cure for the disorder is yet in 
sight. Patients suffering from DMD lose ambulation by their teens, and succumb to respiratory 
and cardiac failure by their late twenties. Although the lack of a functional dystrophin causes 
DMD, a milieu of other secondary factors, including increased oxidative and mechanical stress, 
increased contraction-induced muscle damage leading to muscle atrophy and chronic 
inflammation in muscles, all contributes to dystrophic pathology. Several studies have evaluated 
each aspect of these secondary factors, and have elucidated various therapeutic approaches that 
could be beneficial from a clinical point of view, but few have proven successful or shown to 
have long-term benefits.  
 NF-κB was discovered by Sen and Baltimore, about 25 years ago as a transcription factor 
that could be activated by several external stimuli [163, 164]. In 25 years, discoveries about the 
cellular mechanisms, molecular function and role of the NF-κB pathway have grown 
exponentially. The NF-κB pathway was shown to play a role in many physiological processes, 
and activation of the pathway has been implicated in several disorders, such as cancers, arthritis 
and muscular dystrophy. In DMD, chronic activation of the NF-κB pathway contributes to 
several pathological symptoms including chronic inflammation in muscle, up-regulation of the 
ubiquitin-proteosome pathway causing protein degradation and subsequent muscle atrophy. 
Understanding the molecular properties of the pathway would help develop therapeutic 
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approaches to inhibit the activation of the NF-κB pathway. Over the years, there have been many 
molecules of interest that showed promise as NF-κB inhibitors. One review has estimated that 
almost 800 inhibitors of the NF-κB pathway have been studied so far [48]. Each of the inhibitors 
targets a particular stage of activation of the NF-κB pathway, including upstream molecules of 
the pathway and downstream effector targets. However, a lot remains to be understood about the 
pathway and its mechanism of action, and more discoveries would lead to more efficient 
inhibitors of the pathway.  
 In this thesis, I characterized the role of A20, a naturally occurring critical regulator of 
the NF-κB pathway, in skeletal muscle of dystrophic mice. The role of A20 in skeletal muscle 
was previously unknown and my findings showed that A20 played a role in the inhibition of the 
NF-κB pathway in muscle and also played a role in muscle regeneration. This was a novel 
observation and associated A20 function with muscle regeneration in dystrophic mice. Since 
A20 was shown to play a role in muscle regeneration by inhibition of the NF-κB pathway, I 
studied the potential of A20 as a therapeutic target for amelioration of dystrophic symptoms. 
Over-expression of A20 caused reduction of chronic NF-κB activation, and also by reduction of 
number of fibers with centrally placed nuclei and regeneration, indicating improved muscle 
health. These results confirmed the role of A20 as a negative regulator of the NF-κB pathway, 
and established its role as a novel therapeutic for treatment of DMD. 
My studies demonstrating the role of A20 in dystrophic pathology have shown a clear 
link between A20 and muscle regeneration. However, to establish the therapeutic ability of A20, 
future studies further characterizing the properties of A20 as a NF-κB pathway inhibitor would 
help the effort to take A20 ‘from bench to bedside’. Future studies would include assessing the 
long-term effects of A20 over-expression in mdx mice. This would help establish the long-term 
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therapeutic benefits of A20 in the muscle and confirm its ability to improve muscle health 
throughout the life of the mdx mice. This would also rule out any detrimental effects to the 
muscle due to A20 or vector related toxicity or non-specific effects on other pathways in the 
muscle. Analyzing the effect of A20 treatment on properties of muscle behavior, such as 
membrane stability, muscle force and fatigue would help quantify the improvement in muscle 
health. Studying the efficacy of A20 treatment on larger animal models such as the dog model 
for DMD would help identify the problems associated with gene therapy, such as activation of 
the immune response and bio-distribution.  
A20 is known to be a negative regulator of inflammation, and this negative regulation is 
mainly through the inhibition of the NF-κB pathway. However, studies indicate that A20 might 
play a role in other pathways such as skin differentiation [97], anti-apoptosis [165], angiogenesis 
[122] and the negative regulation of the JNK pathway [97]. However, it is unclear if A20 plays a 
functional role in these pathways via the regulation of the NF-κB pathway or independent of it. 
Thus, understanding the function of A20 in the immune response, other than regulating the NF-
κB pathway would provide more insight to the therapeutic role of A20 in muscle. Although A20 
was shown not to be required for embryonic survival, mice deficient in A20 were reported to die 
within a short period after birth, due to severe inflammation and tissue damage in multiple 
organs [97]. However, in these studies, the effect of A20 deficiency was not analyzed in skeletal 
muscle. A detailed study of the pathways perturbed in the muscles of A20 deficient mice would 
help provide insight to the molecular mechanisms of action of A20 in skeletal muscle. For 
instance, analyzing the effect of lack of A20 genetically introduced in mdx mice would confirm 
the role of A20 on muscle development, regeneration and health. 
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In conclusion, the findings presented in this thesis provide a novel insight to the 
mechanism of the NF-κB pathway in muscular dystrophy, and the effects of inhibition of the 
pathway by A20 on the pathology in skeletal muscle. I have also shown the role of A20 as a 
potential therapeutic target in the muscles of dystrophic mice. Since A20 is a critical negative 
regulator of the NF-κB pathway, I would expect these findings would also initiate the study of 
A20 as a therapeutic target in other disease models, such as in lymphomas and glioblastomas, 
and in autoimmune disorders such as lupus and arthritis.     
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APPENDIX A 
CONTROL EXPERIMENTS PERFORMED  
A.1 SPECIFICITY OF PROBE BINDING IN EMSA ASSAY 
One of the mechanisms to analyze specificity of the NF-κB probe binding in the Electrophoretic 
mobility shift assay (EMSA) is to introduce competitive non-radioactive (cold) specific probe 
and cold mutated probe. The consensus cold probe would bind to the NF-κB protein competing 
with the radioactive probe and displacing it. As an additional control, a mutated probe would be 
unable to bind to the protein, thus unable to displace the radioactive probe. As a control, samples 
were co-incubated with either cold consensus (wild-type) probe or cold mutated probe. The NF-
κB consensus oligonucleotide (sc-2505) and NF-κB mutated oligonucleotide (sc-2511) were 
purchased from SantaCruz Biotechnologies. 
The cold wild-type probe, but not the mutated probe was able to compete out the 
radioactive probe, indicating the NF- κB probe used was specific (Figure 29). 
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Figure 30: Binding of NF-κB probe in nuclear extracts is specific. 
Specificity of NF-κB activation was confirmed using electrophoretic mobility shift assay. C2C12 cells were treated 
with TNF-α (10ng/ml) for 15 and 30 mins and nuclear extracts were obtained. Extracts were incubated with wild-
type probe or mutated probe to assess specificity of radioactive probe binding. 
A.2 COMPARISON OF IN VITRO EXPRESSION OF AAV2-GFP AND AAV8-GFP 
AAV serotypes have differential transduction efficiencies and expression levels in different 
tissue types. The transduction also varies whether the introduction of the transgene was in vivo 
or in vitro. I assessed in vitro GFP expression in C2C12 cells using AAV serotype 2 and 8, 
driven by a cytomegalovirus (CMV) promoter. I assessed expression at different multiplicity of 
infections (MOI) of 1, 10 and 100. At MOI of 10, AAV2 displayed better transduction efficiency 
as compared to AAV8 (Figure 30). This observation corroborates with the earlier published data 
that showed ability of AAV2 to transduce efficiently in vitro compared to weak AAV8 
transduction efficiency [166].  
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Figure 31: GFP expression in C2C12 myotubes.  
C2C12 myoblasts were transduced with either AAV2-CMV-GFP or AAV8-CMV-GFP virus at a MOI of 10 and 
induced to differentiate to form myotubes. BF- Brightfield image.  
A.3 A20 PLASMID EXPRESSION IN C2C12 CELLS 
Upon generation of the AAV-tMCK-A20 plasmid, I looked for in vitro expression of the plasmid 
in C2C12 cells to confirm the expression of A20 protein. C2C12 myoblasts were transfected 
with saline or AAV-tMCK-A20 plasmid and induced to undergo differentiation by serum 
starvation. I observed an increase in the expression levels of A20 protein in the AAV-tMCK-A20 
plasmid transfected cells as compared to mock-transfected cells (Figure 31A, B). This confirmed 
the accuracy of the cloning and efficacy of the plasmid for over-expression of A20 in muscle 
cells.  
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Figure 32: Analysis of A20 plasmid expression in vitro in C2C12 cells. 
C2C12 myoblasts were transfected with AAV-tMCK-A20 plasmid and induced to differentiate to myotubes. A) 
Analysis of A20 protein levels in mock or A20 plasmid transfected cells using Western Blotting. B) Quantification 
of A20 protein levels normalized to GAPDH. Experiments were performed in duplicates.  
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